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Many different glycoproteins and their tumor-associated carbohydrate antigens 
serve as engines for cancer progression and represent important biomarkers 
potentially useful for therapeutic intervention. Among the carbohydrate structures 
modulated in colorectal cancer, of particular interest are the Sda antigen, synthesized 
by the β1,4-N-actylgalactosaminyltransferase B4GALNT2, and sLex antigen, whose 
last biosynthetic step is mediated mainly by the fucosyltransferase FUT6.  Sialyl Lex 
antigen is often overexpressed in CRC and is associated with worse prognosis 
whereas B4GALNT2 and its associated Sda antigen are dramatically downregulated 
in CRC but their role in tumor progression and development is not fully clear.  
To identify correlations between B4GALNT2 expression and clinical parameters, 
“The Cancer Genome Atlas Database” (TCGA), which contains transcriptomic and 
clinical data of hundreds of patients, was interrogated. Transcriptomic data showed 
a dramatic down-regulation of B4GALNT2 mRNA in CRC, compared with normal 
samples. Patients with higher B4GALNT2 mRNA in CRC samples displayed longer 
survival, suggesting a strong relationship between high expression of B4GALNT2 
and lower malignancy. This association was not observed in other malignancies. 
Analysis of mechanisms regulating B4GALNT2 down-regulation in CRC revealed 
that methylation can play a relevant role in B4GALNT2 downregulation in colon 
carcinogenesis as well as miRNA expression. Methylation data of CRC patients 
from TCGA pointed to reduced methylation of the intronic site as a key factor in 
accounting for the general reduction of B4GALNT2 expression in CRC. On the other 
hand, among miRNAs targeting B4GALNT2 miR-204–5p appears to be the most 
plausible candidate inhibiting the glycosyltransferase in CRC. 
In order to clarify the mechanisms linking the B4GALNT2/Sda expression level to 
CRC phenotype, three different CRC cell lines were permanently modified to 
express B4GALNT2 cDNA: the LS174T cell line, in which the constitutively 
expressed sLex antigen was partially replaced by Sda upon B4GALNT2 expression; 
the SW480/SW620 pair, which were derived from the primary tumor and a lymph 
node metastasis respectively, both lacking Sda and sLex antigens.  
In LS174T cells, the expression of B4GALNT2 had little or no effect on the capacity 
to heal a wound or the ability to form clones in standard growth conditions while it 
significantly reduced the ability to grow in poor adherence conditions and the 
 
 
expression of ALDH, a well-known marker of stemness. In SW620 cells, 
B4GALNT2 expression impacted on all the six key aspects of malignancy 
considered in this study, including proliferation rate, clonogenic ability on solid 
support, anchorage independent growth in soft agar, spheroids formation, ability to 
heal a wound and ALDH expression. On the other hand, in SW480 cells the 
expression of B4GALNT2 left unchanged the proliferation rate and the wound 
healing ability. 
The common feature emerging from the analysis of the three cell models is the ability 
of B4GALNT2 to reduce characteristics associated with stemness. 
To clarify the impact of sLex on CRC phenotype, the SW480/SW620 pair were 
permanently transfected to express FUT6 cDNA. In both cell lines, overexpression 
of FUT6 and its associated sLex antigen boosted the clonogenic ability in standard 
growth conditions. Conversely, the growth in soft agar and the capacity to close a 
wound were enhanced only in SW620 cells.  
Transcriptome analysis of the cell lines CRC transfected either with B4GALNT2 or 
FUT6 showed a relevant impact of both enzymes on the modulation of gene 
expression. A “B4GALNT2 signature” common to all three cell lines identified the 
down-regulation of the SPON2 gene, associated with CRC malignancy, as a potential 
pivotal change. 
Overall, current data may help to personalize therapies for CRC patients according 
to the B4GALNT2 levels and support a causal effect of this glycosyltransferase on 
reducing malignancy independently of sLex inhibition. Additionally, these data 
indicate a multifactorial nature of B4GALNT2 regulation, with DNA methylation 
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CHAPTER I- INTRODUCTION 
 




Colorectal cancer (CRC) represents the third most frequently diagnosed type of 
malignancy and the fourth predominant cause of deaths related to cancer in the 
world1,2. New cases are expected to increase by 60% reaching more than 2.2 million 
new while deaths will rise up to 1.1 million by 20301. Global patterns are widely 
divergent but strongly connected to human development, reflecting the 
implementation of western lifestyles that are associated with elevate risk3. Among 
the lifestyle factors identified as part of westernization process are common the 
alcohol consumption, a diet with low usage of fruits and vegetables but high amounts 
of red and processed meats, physical inactivity, obesity, and smoking4,5,6. However, 
the frequency is rising up quickly in those countries with low and middle incomes, 
especially because of social and economic changes7. Globally, only a small 
proportion of CRC burden is associated with family history due to the low frequency 
of these cases8. In high-income countries the incidence rate has been stabilizing as 
many factors have been established as protective including the regular use of aspirin, 
the use of estrogens after menopause and potentially vitamin D assumption as well 
as enhancements in early detection and prevention3,9. 
CRC survival rates drop-off with ageing and is highly dependent on the stage of the 
disease at the time of diagnosis: 90% 5-year survival for locally confined CRC (early 
stage), 70% 5-year survival when cancer is disseminated into the surrounding tissues 
and in the lymph nodes, and 10% 5-year survival in case of distant metastasis 







1.2 Molecular pathogenesis of colorectal cancer 
 
Colorectal cancer arises through the cumulative effects of genetic and epigenetic 
modifications that favor the transition of normal colonic mucosa into invasive 
cancer10,11,12. Different molecular pathways have been demonstrated to contribute to 
colorectal carcinogenesis pointing to the heterogeneous nature of CRC13,14. These 
pathways are characterized by distinct models of genetic instability, firstly proposed 
by Fearon and Vogelstein15. This model comprehends three important features: first, 
colorectal neoplasia results from activation of oncogenes and inactivation of tumor 
suppressor genes due to mutational events; second, at least 5 different mutated genes 
are required for cancer to develop; third, the addition of different genetic alterations 
rather than their order is mainly the driving force of the biologic behavior of the 
disease16. Two major carcinogenesis pathway models have been identified in CRC: 
chromosomal instability (CIN) pathway and microsatellite instability (MSI) 
pathway17.  
The CIN pathway counts for 85% of colorectal cancer cases. In this model are 
contemplated alterations of the number and the structure of the chromosomes and 
mutations in many checkpoint proteins18.  
A crucial mutation affects the tumor suppressor gene APC (Adenomatous Polyposis 
Coli), located on chromosome 5q2119, which is implicated in the Wnt pathway20. 
APC mutations lead to accumulation of cytoplasmic β-catenin which permits its 
translocation into the nucleus and subsequently the binding to the transcription 
factors TCF (T-cell Factor)/ LEF (Lymphoid Enhancer Factor) resulting in 
alterations of the expression of genes involved in proliferation, differentiation, 
migration, adhesion and apoptosis of colon cells20. APC also controls the cell cycle 
progression and stabilization of microtubules, potentially contributing to the primary 
chromosomal instability19. These APC changes are mainly present in adenomas, 
precursor lesions leading to benign colorectal cancer18,15. The early mutations of CIN 
pathway are followed by consecutive events that promote new mutations and 
facilitate the progression of the tumor from benign stages to malignant stages15. The 
transition from adenoma to carcinoma is favored primarily by mutations of  KRAS 
(Kirsten rat sarcoma viral oncogene homolog), a proto-oncogene encoding the 
GTPase protein that regulates the transduction and propagation of extracellular 
signals. This leads to a permanently active state of the protein that allows the cell to 
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elude the apoptotic process and obtain a growth advantage15. More than 90% of 
mutations in KRAS gene occur at codon 12 and codon 13, conferring a different 
oncogenic phenotype. In fact, codon 13 mutations are more involved in the 
adenoma-carcinoma transition whereas codon 12 mutations predispose colorectal 
cancer cells to local invasion and metastasis15. KRAS mutations are followed by the 
inactivation of TP53 (tumor protein p53), a tumor suppressor gene mediating the 
cell-cycle arrest, which can be activated by multiple cellular stresses21. In most cases, 
the two TP53 alleles are inactivated by a combination of a missense mutation that 
silences the transcriptional activity of p53 and a 17p chromosomal deletion that 
eliminates the second TP53 allele. The inactivation of TP53 gene often occurs with 
the transition from large adenomas to invasive carcinomas18. The TP53 loss is often 
accompanied by the LOH (Loss of Heterozigosity) of chromosome 18q (65.4%), 
where the tumor suppressor genes SMAD2, SMAD4 and deleted in colorectal cancer 
(DCC) genes are located22. LOH of 18q has been correlated with high metastatic 




Figure 1. Molecular and morphologic alterations in the adenoma-carcinoma sequence. 
An early mutation in APC gene is followed by additional alterations including KRAS 
oncogene and other tumor suppressor genes such as TP53, SMAD2 and SMAD4. Adapted 
from “Robbins Basic Pathology 9th Edition” (2012) by Kumar, V. et al. 
 
 
The second main CRC pathway is the MSI that represents a form of genomic 
instability responsible of 15% of sporadic colorectal cancer cases and more than 95% 
of Hereditary Non Polyposis Colorectal Cancer (HNPCC) syndrome forms16. MSI 
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origins from the inactivation of the DNA Mismatch Repair (MMR) system23. The 
MMR system is comprised of many interacting proteins including the human MutS 
homologue (MSH) 2 and human MutL homologue (MLH) 1, functioning as a 
proofing machine that identifies and repairs mismatched nucleotides. This process 
increases the fidelity of DNA replications. However, the genes MLH1 and MSH2 
can undergo mutations in the germline leading to instability of short repeat DNA 
sequences known as microsatellites15. Short tandem repeats are small tracts of DNA, 
distributed through the genome every 30-60 kilobases on the order of hundreds 
counts and frequently in humans composed of dinucleotide repeats such as (CA)n or 
(CACACACACAC . . . )23. Microsatellite alleles are present in two copies in most 
individuals. However, during cell replication, often in these areas, errors may occur 
on DNA strand causing a block of DNA polymerase. The MMR enzymes fix the 
errors that are missed by the proofreading activity of DNA polymerase preserving 
the genomic integrity. On the other hand, a defective MMR system will leave the 
genome with microsatellites that are either longer or shorter than the parent cell and 
this phenomenon is termed microsatellite instability (MSI). MSI serves as a marker 
for the loss of DNA MMR function24. A panel of 5 microsatellites markers (D2S123, 
D5S346, D17S250, BAT26 and BAT25) was suggested as a guideline to define  MSI 
level: MSI-H (MSI-H), defined as the presence of instability in 30% of the markers; 
MSI-Low (MSI-L), defined as the presences of instability in 10%–29% of markers; 
microsatellite stable (MSS), defined as no unstable markers23. 
Microsatellite sequences can be present in intergenic regions as well as in the coding 
regions of genes regulating the apoptotic process, cell signaling and cell cycle. 
Usually, in sporadic MSI cancers mutations in KRAS and TP53 genes occur less 
frequently than V600E mutations in BRAF (Murine sarcoma viral oncogene homolog 
B1) oncogene, a member of the RAF family mediating the cellular response to the 
growth signal through the RAS-RAF-MAP kinase axis25. Furthermore, >80% of 
MSI-CRCs harbor mutations of TGFBR2 (TGF-β Receptor 2)23. TGFBR2 mutations 
occur in adenomas either with high-grade dysplasia or progressing to 
adenocarcinoma, and are common in the late and metastatic passages of MSI-H 
CRCs. In addition, SMAD2 and SMAD4 genes, part of the TGF-β pathway, are 
frequently mutated in MSI-H CRCs26. Loss of function of SMAD2 participates, 
independently of SMAD4, to deactivation of TGF-β signaling. Mutations of SMAD4 
leads to unregulated growth induced by TGF-β which may contribute to poor 
5 
 
prognosis in CRC27.  Another alteration originating MSI-H CRCs is the mutation of 
the 2 polyadenine (A8) tracts in exon 10 of ACVR2 (activin type 2 receptor). The 
ACVR2 gene encodes for a transmembrane receptor whose activation is followed by 
the phosphorylation of SMAD2 and SMAD3 proteins causing differentiation and 
growth inhibition. These mutations have been found only in MSI-H CRCs and are 
frequently associated to TGFBR2 mutations.  
Another mutational target in the MSI-H CRCs is BAX, a pro-apoptotic tumor 
suppressor gene. In 50% of CRCs cases, BAX is inactivated by homozygous 
frameshift mutations that facilitate the escape of cells from intrinsic apoptosis 
mechanisms. These mutations, like those of TGFBR2, can be present in the early 
stage of neoplastic progressions. MSI-H CRCs have been correlated with a better 
prognosis than MS stable CRCs, despite the presence of mutations in TGFBR2 and 
BAX genes.  
Additionally, in MSI-H CRC other genes are target of mutations at a lower frequency 
including the MMR genes MSH3 (36.5%) and MSH6 (17.5%), IGF2R (Insulin 
Growth Factor Type 2 Receptor) (22%), BLM gene (16%), PIK3CA (15%), PTGS2 
(G protein-coupled receptor of Prostaglandin-endoperoxide synthase 2) (33%) and 
Cyclin D1 gene (CCND1) (28%). 
Clinically, MSI cancers share specific traits: frequently restricted to proximal colon, 
undifferentiated with a mucinous phenotype, high number of infiltrating 
lymphocytes and a better overall survival/prognosis comparing with patients with 
CIN positive CRC. Morfologically, MSI cancers arise from serrated adenomas or 
hyperplastic polyps, unlike CIN cancers that originate from the classical adenoma-







Figure 2. Molecular and morphological alterations in microsatellite instability model. 
It is characterized by mutations of DNA mismatch repair genes (MLH1, MSH2) leading to 
the accumulation of mutations in short repeat DNA sequences known as microsatellites. 
These mutations may involve genes controlling cell survival, proliferation and cell growth 
such as TGFBR2, apoptosis regulator BAX and oncogene BRAF. Adapted from “Robbins 
Basic Pathology 9th Edition” (2012) by Kumar, V. et al. 
 
 
A distinct molecular subgroup of CRC displays a CpG island methylator phenotype 
(CIMP), consisting of the aberrant hypermethylation of CpG dinucleotide sequences 
present in the promoter regions of genes controlling cell cycle regulation, DNA 
repair, invasion and adhesion, leading to their loss of expression28. CIMP is 
identified in approximately 20%–30% of CRC and is clinically similar to MSI. An 
early event that is correlated with the progression of histologic grades is the silencing 
of the CDKN2A tumor suppressor gene, encoding cyclin inhibitor p16, whose loss 
of function causes uncontrolled cell proliferation, leading to neoplastic 
transformation29.  
The CIMP phenotype can be also divided into CIMP-high and CIMP-low groups, 
depending on the number of methylated markers. The BRAF oncogene mutation is 
often found in CIMP-high CRC and is associated with increase of cell growth, 
promotion of carcinogenesis, and high mortality. However, CIMP-high tumors, 
despite BRAF mutation, are associated with decreased colon cancer mortality. 
Noteworthy, BRAF V600E mutations occur in 90% of CRC cases with sessile 
serrated adenoma (SSA) lesions and are never found in the conventional adenomas25. 
In the serrated pathway BRAF mutations are early events that leads to a state of 
dormancy known as senescence. These mutations happen either in early hyperplastic 
polyps (the serrated precursors) or in the advanced dysplastic serrated polyps. The 
SSA polyps and the BRAF mutation frequently are associated with CIMP-high and 
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MSI-H features; in sporadic settings, CIMP-high microsatellite unstable CRCs 
derive from the serrated pathway29,30.  
 
1.3 CRC diagnosis, staging classification and 
treatment  
 
Colorectal cancer diagnosis is performed histologically by sampling of areas of the 
colon suspected for tumor development, typically during colonoscopy. It is 
confirmed by microscopical examination of a tissue sample. However, the 
invasiveness of the technique limits the execution resulting in an incomplete exam 
for some patients. In those cases, an appropriate CRC diagnosis may be realized by 
Computerized axial tomography scan (CAT scan). This test reveals the presence of 
metastases of the chest, abdomen and pelvis. Other potential imaging tests such as 
Positron emission tomography (PET)  and Magnetic resonance imaging (MRI) may 
be used in certain cases. The latter is often used for rectal lesions to determine its 
local stage and to facilitate preoperative planning5.  
Staging of CRC cancer is referred to TNM (tumor-node-metastasis) system which 
considers how much the initial tumor has spread and the presence of metastases in 
lymph nodes and more distant organs31,32.  
TNM classification from the International Union Against Cancer (UICC) (Figure 
3A) is based on the depth of local invasion (T stage), lymph node involvement (N 
stage) and presence of distant metastasis (M stage). Information of these categories 
is combined into an overall stage definition (stage I, II, III or IV)5.  
Recent technical advances in molecular profiling of tumors have provided gene 
expression data that enable the molecular subtyping of CRC33. Four different 
Consensus Molecular Subgroups (CMS) have been defined: CMS1, CMS2, CMS3, 
CMS4 (Figure 3B). CMS1 is characterized by an upregulation of immune genes and 
is highly correlated with MSI-H. CMS2 represents the canonical pathway of 
carcinogenesis as defined by the adenoma-carcinoma sequence with a higher 
expression of the epidermal growth factor receptor (EGFR) and its ligands such as 
amphiregulin and epiregulin as well as an overexpression of the human epidermal 
growth factor receptor 2 (EGFR2). CMS3 is identified by metabolic dysregulation 
with augmented glutaminolysis and lipidogenesis. CMS4 is characterized by the 
activation of the tissue growth factor (TGF)- pathway and by the epithelial–










Figure 3. TNM and Consensus Molecular Subtype (CMS) classification of colorectal 
cancer. A: TNM defines the stage T as the invasion depth, stage N in case of lymph node 
involvement and stage M in case of metastasis5. B: CMS defines the subtype 1 as MSI 
immune, subtype 2 as canonical, subtype 3 as metabolic and subtype 4 as mesenchymal.34 
 
 
Histologically, CRC can be also categorized depending on the grade of maintenance 
of normal glandular architecture and cytological characteristics (well differentiated, 
moderately differentiated or poorly differentiated)12. About 20% of CRC cases are 
poorly differentiated, presenting a poor prognosis. CRC can present also a mucinous 





of mucins. This cancer features turn out in a very aggressive cancer with a poor 
prognosis35. 
As regards the treatment, surgery is the most common option, depending on several 
characteristics of the tumor such as its location, existence and extent of metastasis. 
If cancer is present only in a single polyp, it can be surgically removed during 
colonoscopy. In early stages of cancer, treatment can include chemotherapy, 
radiotherapy, radiofrequency ablation, cryosurgery or targeted therapy. 
Radiofrequency ablation consists in the use of electrodes to kill cancer cells while in 
cryosurgery freezing techniques are used to destroy the tumor. The most common 





Eukaryotic cells are covered on their surface with a dense group of covalently 
attached sugars (monosaccharides) or sugar chains (oligosaccharides), generically 
referred to as “glycans.” Thus the sugar coat on the cell surface is called 
“glycocalyx”36.  The enzymatic process that produces the glycosidic linkages of 
saccharides to other saccharides, proteins or lipids is known as glycosylation and 
represents not only the most abundant posttranslational modification (PTM), but also 
by far the most structurally diverse37. In nature the spectrum of all glycan structures, 
defined glycome, is vast. In humans, its size is greater than the number of proteins 
encoded by the genome, one percent of which encodes proteins that are involved in 
the synthesis or modification of glycans. Indeed, unlike protein sequences, which 
are primary gene products, glycan structures are secondary gene products38. The 
main glycans are constituted by ten monosaccharide “building blocks”: glucose 
(Glc), galactose (Gal), N-acetylgalactosamine (GalNAc), N-acetylglucosamine 
(GlcNAc), fucose (Fuc), xylose (Xyl), mannose (Man), glucuronic acid (GlcA), 
iduronic acid (IdoA) and 5-N-acetylneuraminic acid (Neu5Ac or sialic acid). The 
structural variety of glycans is enormous and arises from the available number of 
monosaccharides building blocks, glycosidic bond composition, anomeric 
configuration, presence of branching or linear structures and carbohydrates 
modifications such as sulfatation and phosphorylation. Being localized on the 
external surface of cellular and secreted macromolecules, many glycans can mediate  
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or modulate cell–cell, cell–matrix, and cell–molecule interactions crucial for the 
development and function of a complex multicellular organism, including normal 
embryonic development, differentiation, growth, cell signaling, intracellular 
trafficking and localization, disease development, rate of degradation and membrane 
rigidity39. 
Glycan can also play a role mediating interactions between organisms (e.g., between 
host and a parasite or a pathogen). Additionally, protein-bound glycans are abundant 
within the nucleus and cytoplasm, where they can serve as regulatory switches, and 
undergo to rapidly turnover. The glycans linked to proteins can modulate the 
intrinsic properties of the modified protein as its solubility, proper folding, functional 
group orientation and protection from proteases40.  
Glycans are mostly classified according to the nature of the linkage to the aglycone 
(protein or lipid). Glycoconjugates can be divided in five main groups: 
glycoproteins, proteoglycans, glycolipids (glycosphingolipids), 
glycosylphosphatidylinositol (GPI)- linked proteins and O-GlcNAc glycoproteins 
(Figure 4). 
This PhD project is mainly focused on glycoproteins. Glycoproteins are produced 
through the specific action of glycosyltransferases (GTs), a large family of enzymes 
that transfer monosaccharide residues to an acceptor substrate using nucleotide-
sugar donor as activated donor substrates. GTs are specific for a nucleotide-sugar 
donor but can recognize more than one different acceptor. They are defined 
accordingly to the sugar they transfer and the type of linkage they catalyze, being 
localized mainly in endoplasmic reticulum (ER) and Golgi apparatus (GA). Besides 
GTs, glycosidases are also implicated in the metabolism of glycoproteins, acting on 






Figure 4. Common classes of animal glycoconjugates. Proteins can be N‐  linked to Asp (N-
glycans) or O‐ linked to Ser/Thr (O-glycans) of a polypeptide backbone. Proteoglycans are 
glycoconjugates that present one or more glycosaminoglycans such as chondroitin sulfate, heparan 
sulfate and keratan sulfate. An exception is the hyaluronan, a glycosaminoglycan found as a free 
sugar chain. Glycosphingolipids are the most abundant on the cell plasma membrane, made of glycans 
linked to a lipid ceramide. Glycosylphosphatidylinositol (GPI)-linked proteins are attached in the 
outer layer of the plasma membrane by a glycan covalently linked to phosphatidylinositol. Several 
cytoplasmic and nuclear proteins contain O-linked N-acetylglucosamine (O-GlcNAc)42.  
 
 
2.1 Site-specific structural diversity in protein glycosylation 
 
A singular aspect of protein glycosylation is the phenomenon of microheterogeneity. 
Therefore, at any specific glycan attachment site on a protein synthesized by a 
particular cell type, several variations in the structures of the attached glycan might 
be found, and in some cases, the glycan may be missing42. In fact, a polypeptide 
encoded by a single gene can exist in different forms defined as “glycoforms,” each 
constituting a distinct molecular species. For some glycoproteins the 
microheterogeneity at a particular site may be quite restricted, while for other sites 
it may be wide, even within the same glycoprotein species. Mechanistically, 
microheterogeneity might result from the rapidity with which multiple, sequential, 
partially competitive glycosylation and deglycosylation reactions occur in the 
endoplasmic reticulum (ER) and Golgi system, through which a newly synthesized 
12 
 
glycoprotein passes, along with the lack of a template for directing the synthesis and 
the accessibility of glycans at a site to the modifying enzymes42.  
 
2.2 Cell biology of glycosylation 
 
The biosynthesis of major classes of eukaryotic glycans takes place within ER and 
Golgi compartments. Proteins originating in the ER are either co-translationally or 
post-translationally modified with glycans at various points along their way to their 
final destinations42. Oligosaccharides are linked to proteins by two main types of 
linkages. In the first, referred to as N- glycosylation, a GlcNAc residue is linked to 
the amide side chain of asparagine. In the second, referred to as O-glycosylation, a 
GalNAc residue is linked to the hydroxyl group of serine or threonine36.  
 
2.2.1 N-linked glycosylation 
 
N-linked glycosylation is the most studied form of protein glycosylation in 
eukaryotic organisms (about 90% of eukaryotic proteins carry N-glycans)43,44.  
N-glycosylation biosynthesis (Figure 5) begins with the synthesis of a lipid- linked 
oligosaccharide (LLO) constituted by 2 GlcNAc, 9 Man and 3 Glc residues 
covalently attached to a lipid dolichol on the cytoplasmic face of ER44. LLO 
biosynthesis is executed by a set of GTs that are encoded by asparagine linked 
glycosylation (ALG) genes. The formed glycan is then transferred to an asparagine 
(Asn) residue of a nascent polypeptide by a multi-enzyme complex named 
oligosaccharyltransferase (OST). There is a minimal consensus sequence, comprised 
of an Asn-X-Ser/Thr tripeptide where X can be any amino acid except proline, that 
can accept a N-glycan. These steps are followed by a series of reactions trimming 
N-glycans: trimming of two Glc residues by α-glucosidases I and II originates 
GlcMan9GlcNAc2 structure that serves as a ligand for two chaperones, calnexin and 
calreticulin, helping the protein folding. Misfolded proteins are translocated back to 
the cytosol to be degraded in the proteasomes44.  
Proteins that are properly folded pass to the Golgi complex where the first process 
is the demannosylation by the Golgi α-mannosidase I, forming the Man5GlcNAc2 
structure, the main substrate for N-acetylglucosaminyltrasferase-I (GnT-I, product 
of the MGAT1 gene). As the pathway progresses through the Golgi complex, the 
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GlcNAc1Man5GlcNAc2 structure can be further modified by the removal of 2 Man 
residues by α-mannosidase II and by the addition of a second GlcNAc residue, 
catalyzed by N-acetylglucosaminyltrasferase-I (GnT-II, product of the MGAT2 
gene).  
N-glycans can be further added of Gal, Fuc, sialic acid, and sulfate to the antennae 




Figure 5. Schematic representation of N-linked glycoproteins biosynthesis. The entire 
oligosaccharide Glc3Man9GlcNAc2 is transferred to the asparagine residue of a nascent 
polypeptide chain by the oligosaccharyltransferase (OST) complex. After the action of 
glucosidase I and II (Glcase I and II), protein glycosylation contributes to the quality control 
of protein biosynthesis, through the chaperones calnexin (CNX) and calreticulin. Unfolded 
glycoproteins are moved to cytosol, where a N-glycanase (N-Gase) removes the N-glycans, 
and lately to the proteasome for degradation. Properly folded proteins are transported to the 
Golgi, where glycosyltransferases and glycosidases modify the various antennae of the 
glycans to give more complex structures. UGGT, UDP– glucose-glycoprotein 
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glucosyltransferase; Hmt1p, HnRNP methyltransferase 1; Mnl1p, mannosidase-like protein 
1; Man, α-mannosidase; GnT, N-acetylglucosaminyltransferase45.  
 
N-glycans share a common sugar core structure 
(Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAcβ1-Asn) and are divided in three 
main types: high mannose, in which only mannose residues are linked to the core; 
complex, in which the core is extended by GlcNAc residues in both mannose arms; 
and hybrid, in which the Manα1,6 arm of the core contains only mannose residues 
whereas the Manα1,3 arm is extended by complex type structures. They also include 
some hybrid and complex type glycan determinants (Figure 6): bisecting GlcNAc 
structure, where a third GlcNAc residue can be linked to the innermost mannose 
residue by the enzyme GlcNAc-transferase III; paucimannose structure, truncated 
structure from the N-glycan core; core fucosylated structures, where a fucose residue 
is linked to the first GlcNAc of the chain by the fucosyltransferase VIII46.  
 
 
Figure 6. Main types of N-glycans in vertebrates. Types of N-glycans present in a mature 
glycoprotein: high mannose, hybrid and complex. All types share a common core glycan 
structure that can be elongated by core fucosylation, bisecting GlcNAc and other glyco 
determinants. Paucimannose structures are characterized by truncated glycans46.  
 
 
The glycosyltransferases involved in the N-glycan synthesis in the ER are mainly 
multitransmembrane proteins placed in the ER membrane whereas the 
glycosyltransferases in Golgi compartments are generally type II membrane proteins 
with a small cytoplasmic amino-terminal domain, a single transmembrane domain, 
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and a large lumenal domain elongated with a stem region extending from the 
membrane and a globular catalytic domain. The stem region is often cut off by the 
action of signal peptide peptidase-like proteases, particularly SPPL-3, leaving the 
catalytic domain into the lumen of the Golgi apparatus and allowing its secretion. 
Therefore, many extracellular form of glycosyltransferases are present in tissues and 
sera44.  
Glycans are regularly turned over by degradation and the enzymes mediating this 
process cleave glycans either at the outer (nonreducing) terminus (exoglycosidases) 
or internally (endoglycosidases)42. Some terminal monosaccharide units such as 
sialic acids could be removed and new units added during endosomal recycling, 
without degradation of the underlying chain. The final complete degradation of most 
eukaryotic glycans generally takes place in the lysosome through multiple 
glycosidases. Once degraded, the individual monosaccharide units are exported from 
the lysosome to the cytosol for reutilization. In contrast to the relatively slow 
turnover of glycans stemmed from the ER-Golgi pathway, the nuclear and 
cytoplasmic O-GlcNAc monosaccharide modifications are quite dynamic42. 
 
2.2.2 O-linked glycosylation 
 
Mucins are heavily O-glycosylated proteins (glycan moiety may comprise 80% of 
the molecule weight) that can be soluble, secreted or expressed in the cell 
membrane47. They are present at many epithelial surfaces including respiratory, 
reproductive and gastro- intestinal tracts, playing an important role in the protection 
against pathogens48. Mucin-type O-glycosylation, the most common type of O-
glycosylation, involves the attachment of a GalNAc residue to serine (Ser) or 
threonine (Thr) of a nascent protein49. This first step initiates in Golgi apparatus and 
is controlled by a large family of up to 20 genes (GALNT1-GALNT20) encoding 
polypeptide-N-acetyl-galactosaminyltransferase (ppGalNAcT). Subsequently, O-
linked GalNAc residues can be further modified or extended by specific GTs, 
resulting in several heterogeneous structures49. In literature are described eight O-
GalNAc glycan core structures, being those from core 1 to core 4 the most common 





Figure 7. Common O-GalNac glycan cores structures and their biosynthetic pathway. 
Biosynthesis is initiated by up to 20 ppGalNAcTs forming the Tn antigen, which may be 
elongated by the core 1 synthase (C1GALT1) or core 3 synthase (B3GNT6), forming the T 
antigen and core 3 structures, respectively. Both Tn and T antigens may be modified by 
sialic acid to form sialyl-Tn or sialyl-T antigens, correspondingly. Another common core 
structure contains a branching N-acetylglucosamine attached to core 1 and is named core 2. 
The different core structures can be further elongated and modified by several GTs 
originating various complex O-GalNac glycans49. C2GNT2, core 4 synthase; C2GNT1/3, 
core 3 synthase; ST3GAL1, β-galactoside α-2,3-sialyltransferase 1; ST6GALNAC1, 
GalNAc α-2,6- sialyltransferase 1.  
 
 
2.3 Glycosylation in cancer  
 
Altered glycosylation represents a hallmark of cancer cells, associated with 
malignant transformation and tumor progression40. Some major factors that affect 
protein glycosylation in tumor cells are: level of expression of specific 
glycosyltransferases; localization of glycosyltransferases in the secretory 
compartments and other cellular compartments, such as the nucleus and 
mitochondria; expression of specific molecular chaperones that regulate protein 
folding and quality control of glycoproteins and glycosyltransferases; levels of 
expression of specific glycosidases in the processing pathway; availability of protein 
substrates and levels of nucleotide sugars; competition between glycosyltransferases 
for similar glycan acceptors50. Numerous glycosylation alterations have been 
described in cancer including the incomplete synthesis and expression of truncated 
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glycan structures, increased expression of complex branched N-glycans, de novo 
expression of terminal sialylated glycans, and altered fucosylation40. 
 
In this section will be discussed some of the most relevant cancer-associated 
glycosylation changes.  
 
2.3.1 1,6 branching 
 
One of the most consistently alterations following neoplastic transformation is a shift 
toward the synthesis and expression of larger Asn-linked oligosaccharides because 
of the addition of 1,6-linked lactosamine antennae51. The  increase of β1–6 
branching structures is due to the enhanced expression of N- 
acetylglucosaminyltransferase 5 (GlcNAcT-V)51 (Figure 8), resulting from the 
enhanced expression  of MGAT5 gene42. These structures have been found to play 
a causative role in tumor growth and metastasis. Studies conducted in MGAT5 
deficient mice revealed that growth rate of breast cancer resulted decreased and 
metastasis formation was almost completely inhibited52. Cells derived from animal 
models lacking Mgat5 expression exhibited increased contact inhibition and 
substratum adhesion than Mgat5-expressing cells. Nevertheless, the relationship 
between β1,6-branching and increased growth and metastasis is probably due to 
more than one mechanism. The sugar chains produced by MGAT5 are distributed 
on various cell surface molecules, including growth-promoting receptors (such as 
PDGFR and EGFR) and receptors with arrest and morphogenic activity (such as 
TGF-βR and CTLA-4), and are used as a ligand by galectin-3 which, consequently, 
forms a lattice which stabilizes the receptors on the cell surface. However, growth-
promoting receptors express an average higher number of N-linked glycans than 
receptors with arrest/morphogenic activity. As a consequence, the galectin-3-
mediated stabilization of membrane receptors favors highly-branched, growth 
promoting receptors. MGAT5 expression is regulated by the Ras pathway, thus 
explaining its close association with cancer.  However, in many circumstances 
MGAT5 activity is counteracted by that of a competing enzyme, N- 
acetylglucosaminyltransferase 3 (GlcNAcT-III), encoded by the gene MGAT3, 
which catalyzes the formation of glycans with a bisecting GlcNAc β1,4-linked to the 
innermost Man residue of the core. This modification suppresses the processing and 
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elongation of N-glycans and decreases N-glycan branching structures. In fact, 
overexpression of GlcNAcT-III in several cancer types inhibits the function of 




Figure 8. Bisected and branched N-glycan structures. Neoplastic progression is 
accompanied by an increase of GlcNAcT-V activity that leads to the formation of branched 
N-glycans. These structures can be further elongated and recognized by galectins and/or 
selectins, lectins playing an important role in cancer progression. The formation of bisected 
N-glycans by the expression of GlcNAcT-III is also shown42.   
 
2.3.2 T, Tn and sialyl-Tn antigens  
 
In many cancers truncation of O-glycosylation pathways leads to expression of 
simple O-glycans47. These truncated glycan structures include the T , Tn  and Sialyl-
Tn (STn) antigens50. The Tn antigen is formed by a GalNAc linked to Serine or 
Threonine (GalNAcα1-O-Ser/Thr). This sugar can be substituted by α2,6-linked 
sialic acid, leading to the formation of sialyl-Tn antigen (NeuAcα2–6GalNAcα1-O-
Ser/Thr), or by a β1,3-linked galactose, forming the Thomsen-Friedenreich (T) 
antigen (Galβ1-3GalNAcα1-O-Ser/Thr), or by a β1,3-linked GlcNAc, forming the 
core 3 structure53. The β1,3-galactosyltransferase which synthesizes the T antigen 
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(T-synthase) is peculiar because it requires the presence of a molecular chaperone, 
the product of the gene Cosmc that, in the endoplasmic reticulum, binds to T 
synthase preventing its ubiquitination and degradation in the proteasome50. In 
normal colonic tissues, T antigen is not expressed because it is masked by sialylation 
but it is highly expressed in colon carcinoma and in liver metastases54. It was showed 
that the presence of cancer cells expressing the T antigen induce the expression of 
galectin-3 by endothelial cells. This carbohydrate structure interacting with galectin-
3 might mediate both the homotypic aggregation of cancer cells and the docking of 
tumor cells to endothelial cells. The homotypic aggregation protects cancer cells 
from anoikis induced by the absence of adhesion to extracellular substrates50. 
Inhibition of T antigen with specific antibodies was found to reduce lung metastasis 
formation by breast cancer cells55. However, in breast cancer, besides T antigen 
accumulation, there is an overexpression of ST3Gal1 which synthesizes sialyl T 
antigen. In animal models tumor progression was linked to the increased expression 
of the enzyme, suggesting the possibility that it acts as a tumor promoter55.  Sialyl-
Tn antigen, mainly synthesized by ST6GalNAc1, is expressed by many 
malignancies, including stomach, liver, pancreas. A general mechanism possibly 
explaining the over-expression of Tn and sTn antigens in cancer is the somatic 
inactivation of the gene Cosmc53. T and sialyl Tn antigens are carried mainly by a 
high molecular weight splice variant of CD44  and MUC1 in colon cancer, by MUC2 
in gastric cancer and MUC1 in breast cancer50.  
2.3.3 Core fucosylation  
 
Fucosylation is one of the most important types of glycosylation in cancer56,57. This 
reaction is regulated by several enzymes known as fucosyltransferases that may 
differ between glycoproteins and glycolipids but share the donor substrate, GDP-
fucose56. The α1-6 fucosyltransferase VIII (FUT8) catalyzes the addition of a fucose 
to the innermost GlcNAc residue of N-glycan structures resulting in core 
fucosylation. Increases in core fucosylation have been reported in hepatocellular 
carcinomas (HCC), specifically, fucosylation of a-fetoprotein (AFP)58.  Fucosylated 
AFP is a well-known tumour marker for hepotacarcinomas, but sometimes is also 
increased in benign liver diseases such as chronic hepatitis and liver cirrhosis. The 
molecular mechanism underlying the production of fucosylated AFP in HCC is 
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complicated. The enhancement of FUT8 is insufficient for the production of 
fucosylated AFP in HCC. A donor substrate, GDP-fucose, is a more important 
regulatory factor for the fucosylation in HCC57.  
The presence of core fucose in N-glycans also regulates the process of antibody 
dependent cellular cytotoxicity (ADCC). Indeed, core fucose deletion from human 
immunoglobulin IgG1 enhances ADCC activity59. Additionally, core fucosylation 
may be involved in the modulation of the activity of growth factor receptors, 
integrins and cadherins. The absence of core fucosylation inhibits TGF-β/Smad2/3 
signaling and epithelial-mesenchymal transition of renal epithelial cells is reduced60.  
 
2.3.4 Sialyl Lewis antigens  
 
Sialyl Lewis antigens are terminal structures that can be found on N-glycans, O-
glycans and in glycosphingolipids. They are frequently overexpressed in carcinomas 
and the degree of their overexpression has been correlated with tumor progression 
and poor prognosis in (among others) colorectal, lung and renal cancer61,62,63. Sialyl 
Lewis x (sLex) derive from the 1,3-fucosylation of a 2,3-sialylated type 2 chain, 
while the sLea
 
antigen derives from  the 1,4-fucosylation of a 2,3-sialylated type 
1 chain (Figure 9)64. The sLea
 
tetrasaccharide is a tumor biomarker detected by the 
monoclonal antibody CA19.9 widely used for the clinical management of patients 
with gastrointestinal cancers65. 
The terminal steps for the Sialyl Lewis structures biosynthesis include the action of 
sialyltransferases (STs) and fucosyltransferases (FUTs). ST3GALs transfer a sialic 
acid residue in α2,3 linkage to a galactose. While α-2,3 sialylation of type 1 chains 
can be mediated only by ST3GAL3, sialylation of type 2 chains can be mediated by 
ST3GAL3, ST3GAL4 and ST3GAL664. FUTs transfer a fucose residue to an 
acceptor, normally galactose or GlcNAc. There are five α-1,3-FUT (FUT3, FUT4, 
FUT5, FUT6 and FUT7) able to synthesize sLex, while sLea
 
can be synthesized only 
by FUT3.  
These structures are selectin ligands and, when present at the surface of cancer cells, 
interact with selectins expressed by the endothelial cells, regulating the metastatic 
cascade by favoring the arrest of tumor cells on endothelium66. Among all selectins, 
E-selectin is the major receptor involved in adhesion events during metastasis, 
although P- and L-selectin can also contribute to that process67,68. Indeed, studies in 
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animal models showed a decrease in tumor metastasis after the inhibition of P-
selectin-mediated interactions of platelets with sLex/sLea antigens present on the 
surface of cancer cells69.  
Studies in colon cancer elucidate a clear lack of relationship between 
sialyltransferases/fucosyltransferases modulation and sLex
 
expression, suggesting 
that, in this type of cancer, the expression of sialyl lewis antigens may be due to 
other mechanisms70,71
 





































Figure 9. Structures and glycosyltransferases involved in the biosynthesis of Sialyl 
Lewis antigens. Sialyl Lewis x (type 2 chain structure) and Sialyl Lewis a (type 1 chain 
structure) are synthetized by sequential enzyme reactions, ending with the action of 
sialyltransferases and fucosyltransferases64.  
 
In this project, the focus is on the enzyme B4GALNT2 that synthesizes the Sda
 
antigen and indirectly influences the expression of sLex
 
antigen, affecting malignant 
transformation.  
 
2.3.5  B4GALNT2 enzyme and Sda antigen  
 
The Sda antigen belongs to the “non ABO” histo-blood group system, is expressed 
on erythrocytes and identified in secretions of almost 95% of individuals with 
Caucasian origin72. It is formed by an α2,3 sialylated type 2 chain to which a GalNAc 
residue is  β1,4 linked to Gal (Figure 10). The enzyme that catalyzes the addition of 





antigen has been primarily identified in the gastrointestinal tract on the 
borders of epithelial cells and in the goblet cells of the large intestine, being 
expressed by N- or O-linked glycans chains of glycoproteins as well as by long 
gangliosides71. Several lectins have been used for the study of Sda antigen including 
Vicia villosa B4 lectin and Helix pomatia lectin73,74.  
Figure 10. Last biosynthetic step of Sda biosynthesis. The addition of β1,4-linked GalNAc 
residue to Gal, mediated by B4GALNT2, leads to the formation of Sda antigen. 
 
The enzyme B4GALNT2 was firstly documented in guinea pig kidney
 
and finally 
identified in the colon of several species including human, rat and pig75. B4GALNT2 
gene maps in chromosome 17 and contains 11 exons. Two main transcripts have 
been identified in humans, only differing from the exon 1(Figure 11)71, which exists 
in a short exon 1 (1S, 38 base pairs) and in a long form (1L, 253 base pairs). These 
two transcripts harbor a translational start site, originating at least two different 
transmembrane peptides: the long form with a very long cytoplasmic domain and a 
short form with a conventional length cytoplasmic domain. It was demonstrated 
experimentally that the short B4GALNT2 form presents a higher enzymatic activity 
comparing with the activity of the long form in the CRC cell line LS174T76,77. Very 
recently, it has been shown that while the short form localizes exclusively in the 
Golgi apparatus, the long form localizes also on the plasma membrane and in post-
Golgi vesicles78.  
In the genomic sequences upstream of exons 1L and 1S there are CpG islands, thus 
suggesting that DNA methylation can contribute for the regulation of B4GALNT2 
gene expression79. In fact, B4GALNT2 methylation was found in gastric cancer cases 
and in the majority of gastric and CRC cell lines80. Anti-DNA methylation treatment 







Figure 11. Organization of the human B4GALNT2 gene and its transcripts. The gene is 
comprised of 11 exons with at least three alternative first exons: exons 1S, 1L and 1M. Exon 
length (in bp) is reported above the exons. Numbers below the introns indicate the 
approximate intron length expressed in kb. The coding regions are shown in gray. The length 
of exon 11 refers to the coding portion only. The short and long transcript forms derive by 
the alternative presence of exon 1S or 1L. Both contain a translational start codon and give 
rise to two transmembrane proteins differing in the amino-terminal portion. The predicted 
transmembrane domain is presented in dark gray. The “soluble form” is originated by exon 
1M missing a translational start codon. Two possible ATG starting codons of this putative 
transcript are inside exon 2, around the end of the transmembrane encoding sequence76.  
 
Although only partially understood, the role of B4GALNT2 and Sda
 
antigen appears 
to be wide and different in different tissues and organs. Examples are provided by 
the regulation of hemostasis in a murine model, by acting on the clearance of the 
Von Willebrand factor81, a role in embryo attachment82
 
and a role in preventing 
muscle degeneration in a mouse model of Duchenne muscular dystrophy83,84. 
However, one of the most likely role of the Sda antigen is to prevent the cell surface 
attachment of microorganisms expressing receptors for α2,3-sialylated glycans83. In 
fact, a recent study has shown that B4GALNT2 is the major factor restricting the 
infectivity of influenza virus strains expressing receptors for α2,3-sialylated 
glycans85.  
 
In colorectal cancer, B4GALNT2 activity and Sda antigen are dramatically reduced 
compared to normal colon mucosa86,87. As described before, the selectin ligand sLex 
antigen is overexpressed in colorectal cancer, contributing to cancer progression and 
metastasis. The overexpression of sLex
 
antigen in CRC is not supported by a 
concomitant increase of the fucosyltransferases and sialyltransferases involved in its 
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biosynthesis, which are expressed at comparable levels in normal colon mucosa and 
CRC. A role for B4GALNT2 and Sda
 
in the regulation of sLex
 
expression has been 
proposed. The similarity between the Sda
 
and sLex antigen structures suggests that 
their biosynthesis might be mutually exclusive77,88 (Figure 12A). This hypothesis is 
further strengthened by the fact that sLex cannot act as an acceptor for B4GALNT2. 
Both derive from the substitution of an α2,3-sialylated type 2 chain: by a GalNAc 
residue β1,4 linked to a galactose by B4GALNT2 for Sda antigen and by a α1,3 
fucose linked to a GlcNAc for sLex. It was demonstrated in vitro that forced 
upregulation of B4GALNT2 in CRC cell lines resulted in the down regulation of 
sLex antigen and expression of Sda carbohydrate89, with a concomitant reduction of 
the metastatic ability. In colon specimens, mucins from normal colonic mucosa 
express high levels of Sda
 
and low levels of sLex90. Since FUT6 is the main 
fucosyltransferase responsible for sLex
 
biosynthesis in colonic tissues and is nearly 
unchanged in cancer71, a model for the regulation of sLex
 
expression by B4GALNT2 
suggests that the low level of B4GALNT2 present in colon cancer tissues is 





Accordingly, a significant linear relationship between sLex
 
and the 




Figure 12. Biosynthetic pathway and expression of Sda and sLex in CRC. A: 
Biosynthetic pathway of sLe
x and Sda antigens, showing the competition between 
B4GALNT2 and FUT6. B: In CRC, the increase of sLe
x expression is not correlated with 
an increase in fucosyltransferase expression (arrows with same shape) meanwhile the 
reduced B4GALNT2 expression in cancer tissues (slight arrow) is responsible to change the 
equilibrium towards sLe





3. Cancer stem cells  
 
Colorectal cancer as well as other types of tumors is frequently composed of 
heterogeneous cell types, and tumor initiation and growth are driven by a small 
subset of cells, termed cancer stem cells (CSC) or tumor-initiating cells91. 
Stem cells are described as a population of cells capable to self-renew indefinitely, 
form single cell derived populations and differentiate into various cell types92. Stem 
cells found in human tissues are generally multipotent and can originate a restrict 
number of cell types unlike embryonic stem cells (ESCs) that are pluripotent and can 
originate any cell type93,94. Recently, great emphasis has been given to the discovery 
that somatic cell can undergo de-differentiation through the expression of specific 
transcription factors such as Oct4 (octamer-binding transcription factor 4), SOX2 
(sex determining region Y box 2), c-Myc and KLF4 (Kruppel-like factor 4)93. These 
reprogrammed cells have been called induced pluripotent stem cells (iPSC) and 
share many characteristics with ESCs but present also differences, for example 
different DNA methylation95. Stem cells have been recognized also in cancer tissues 
where they acquire the ability to survive from conventional treatment and escape 
from the immune system. Therefore, they can cause recurrence of cancer because 
even few surviving cancer stem cells (CSC) are sufficient to form a new tumor92. At 
present, the mechanism of CSC development is still controversial96. One theory 
suggests that they can be due to oncogenic mutations accumulating within adult stem 
cells, which leads to their uncontrolled proliferation, retaining stemness. The second 
theory considers cellular dedifferentiation from a cancer cell into a stem-like state97. 
Regardless the mechanism of development, CSCs are identified by several universal 
markers; however, a specific marker has not yet been found common to different 
cancer types. In colon cancer Oct4, SOX2, c-Myc, and KLF4 (that can 
dedifferentiate cells in iPSC) together with NANOG (Homeobox protein NANOG) 
are overexpressed, conferring the cells a stem cell like phenotype94. Other most used 
markers for CSC identification are CD133 and CD44. CD133 (Prominin-1), a five 
transmembrane domain glycoprotein, is a well-known cell surface marker that is 
expressed in HSCs and progenitor cell subpopulation98. N-linked glycan 
modification on CD133 regulates its cell surface localization. It has been reported 
that cells CD133+ isolated from primary CRC were able to originate tumors in mice. 
CD44, a transmembrane glycoprotein that mediates lymphocyte homing and HA 
26 
 
(hyaluronan)-dependent cell adhesion an present in various cells types, including 
hematopoietic system, is overexpressed since early events of colorectal cancer 
development because its expression is regulated by the Wnt pathway, often altered 
in CRC99. CD44 is a sLex carrier and a selectin ligand100. Single CD44+ cells are 
able to form tumor spheres with stem cell characteristics that give rise to tumors 
when injected in mice99,101.  
There are other markers under study for the identification of colorectal CSCs. 
SALL4 (Sal-like protein 4) controls self-renewal and pluripotency in embryonic 
stem cells, evidences suggest that it is regulated by the Wnt pathway102. Moreover, 
it has been found in plasma of patients with local CRC103. ABCG2 is a member of 
ATP binding cassette superfamily, therefore involved in drug resistance104, and is 
associated with proliferation and maintenance of CSCs, as well as tumor 
formation105. STAT3 is a transcription factor correlated with increased proliferation 
and invasion of cancer cells106, its presence has been reported in tumor-initiating 
CD133+ cells106. EpCAM and LGR5 are other potential CSC markers. EpCAM 
(Epithelial cell adhesion molecule) is principally expressed on tumors of epithelial 
origin and is enriched in colon tumors relative to normal colon. EpCAM 
High/CD44+ cells can originate tumors if injected in mice92. LGR5 (Leucine-rich 
repeat-containing G-protein coupled receptor 5) is a newly identified marker whose 
knockdown causes tumor regression, while its recovery induces tumor growth and 
recurrence107. Finally, aldehyde dehydrogenase 1 (ALDH) is considered a typical 
marker of normal and cancer stem cells. Its expression is increased in CRC 
correlating with poor prognosis. In fact, ALDH High cells present CSCs features, 
such as self-renewal, in vivo tumor growth capacity and resistance to 
chemotherapy108. Moreover, it has been reported that patients with high ALDH 
before chemoradiation present recurrence after surgery, thus ALDH can predict the 
prognosis of patients receiving post-surgery chemoradiation109. 
4. Epigenetic mechanisms of gene expression regulation 
Epigenetic mechanisms act a control system within a cell regulating gene expression 
and silencing110. This control varies between tissues and plays an important role in 
cell differentiation. Additionally, epigenetic modifications drive the differences in 
27 
 
gene expression between cells, resulting in the unique function of specific cell 
types111.   
The major epigenetic mechanisms include DNA methylation and miRNA 
expression112,113.  
4.1 DNA methylation  
 
DNA methylation is an epigenetic mechanism involving the covalent transfer of a 
methyl group to the cytosine bases of DNA by DNA methyltransferases 
(DNMTs)114,115. The majority of DNA methylation occurs on cytosines that precede 
a guanine nucleotide or CpG sites. DNA methylation is essential for numerous 
cellular processes including tissue-specific gene expression regulation, genomic 
imprinting, and X chromosome inactivation116. Importantly, DNA methylation in 
different genomic regions may exert different influences on gene activities based on 
the underlying genetic sequence112. Within intergenic regions, one of the main roles 
of DNA methylation is to repress the expression of potentially harmful transposable 
and viral genetic elements116. In the genome sites containing a high density of CpG 
are denominated CpG islands, stretches of DNA roughly 1000 base pairs. The 
majority of gene promoters, about 70%, are located within CpG islands. The 
methylation of CpG islands results in stable silencing of gene expression. Like these 
sites, the methylation of regions called CpG island shores, located 2 kb far from CpG 
islands, is highly correlated with reduced gene expression. On the other hand, DNA 
methylation of the gene body is associated with a higher level of gene expression in 
dividing cells.117  
There  are  two  general  mechanisms  by  which  DNA methylation inhibits gene 
expression: first, modification of cytosine bases can inhibit the association of some 
DNA-binding  factors  with  their  cognate  DNA  recognition sequences; second, 
proteins that recognize methyl-CpG can stimulate the repressive potential of 
methylated DNA28. 
DNA methylation in CpG-rich promoters of genes is a common feature of human 
cancers.118 Indeed, aberrant hypermethylation of gene promoters is recognized as a 
major mechanism associated with inactivation of tumor-suppressor genes in cancers, 
and it is involved in almost all the critical steps of oncogenesis28. In colorectal 
cancers, epigenetic changes in selected genes are tightly related to neoplastic 
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transformation, and aberrant DNA methylation appears to arise very early in the 
colon (initially in mucosa of normal appearance), and may be part of the age-related 
defect in sporadic colorectal cancers118. 
Kawamura et al. showed that the CpG islands of the B4GALNT2 gene encoding the 
enzyme responsible for the synthesis of the Sda structure, were heavily methylated 
and this methylation was closely correlated with the transcriptional silencing of the 
B4GALNT2 gene80. In another work Wang et al. demonstrated the role of DNA 
methylation in the promotor region of B4GALNT2 in the suppression of the Sda gene 
using as models gastrointestinal cancer cell lines, event that was substantially 
relieved by treatment with the DNA methylation inhibitor, 5-aza-2'-deoxycytidine 




miRNAs have been described as another important epigenetic mechanism that 
influences gene expression110. MicroRNAs (miRNAs) are a class of endogenous 
small, noncoding, RNA fragments, 22-nt long, that are processed from larger (80-
nt) precursor hairpins by the RNase III enzyme Dicer into miRNA:miRNA* 
duplexes119. One strand of these duplexes associates with the RNA induced silencing 
complex (RISC), whereas the other is generally degraded. The miRNA–RISC 
complex can bind to the 3-untranslated region (UTR) of the target mRNA and 
repress gene expression by inhibiting translation or inducing RNA degradation120. 
RNA interference (RNAi) is one of the processes by which miRNAs regulate gene 
expression120. Each small RNA forms a gene-silencing ribonucleoprotein, specific 
for the DNA target sequence according to the level of complementarity. Thus, the 
effect of miRNAs on their target genes is based on the degree of homology between 
the sequences of the miRNA and the target gene. The homology that controls the 
specificity of miRNAs is dependent on 6-7 nucleotides that bind to the 3-UTR of 
their target mRNAs120. Many combinations of miRNAs and mRNAs are possible, as 
miRNAs can either bind completely to a complementary sequence of mRNAs or 
incompletely because some nucleotides can have a mismatch complement base. The 
number of miRNA and mRNA pairs is increased because one miRNA can target 
multiple genes, and one gene can also be targeted by multiple miRNAs121. miRNAs 
regulate numerous physiological processes, including development, epithelial-
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mesenchymal transition (EMT), regulation of homeostasis and metabolism21. 
However, many miRNAs appear to be deregulated in many diseases, including 
cancer. They are involved in cell transformation from normal to malignant status, 
including in colorectal cancer (CRC)21. miRNAs seem to influence genes involved 
in the initiation and progression of CRC, including some of the known frequently 
inactivated genes APC, TGFBR2, TP53, SMAD4, PTEN, constitutively activated 
KRAS or overexpressed MYC122. In addition to protein-coding genes and mRNAs, 
there are also miRNAs that can regulate CRC tumor-initiating cells, such as miR-
34a5,6, miR-106b7, miR-1408 , miR-146a9, miR-18310, miR-20010, miR-20310, 
miR-21511, miR-302b12, miR-32813, miR-36314, miR-37115 and miR-45116. In 
CRC, miRNAs  are thus involved in the regulation of many features of cellular 
transformation113. Furthermore, miRNA deregulation is also correlated to 
angiogenesis, proliferation and migration of cancer cells in CRC, hence contributing 
to cancerogenesis and invasion123. miR-494, miR-598 and miR-17-3p promote cell 
proliferation, migration and invasion. miR-106a and miR-7 affect apoptosis of CRC 
cells or resistance to apoptosis. miR-221 and miR-214 reduce autophagy in CRC 
cells. miR-192/215 and miR-19b-1 control some metabolic pathways. miR-508 
induces the stem like/mesenchymal subtype in CRC by affecting the expression of 
cadherin CDH1 and the transcription factors ZEB1, SALL4 and BMI1122. miR-21-
5p seems to have epigenetic effects in CRC by blocking the activation of DNA 
demethylation. miRNAs can also control genes of signaling pathways in CRC21. NF-
kB regulates immune response and inflammation processes, and is associated with 
multiple miRNAs such as miR-150-5p, miR-195-5p and miR-203a in 
carcinogenesis. miRNAs have shown great clinical value in the diagnosis, treatment 
and prognosis of CRC124. Developing appropriate miRNA biomarkers is essential 
for early stage CRC diagnosis. The differential miRNAs and miRNA regulated 
genes were screened in early stage CRC tissues, precancerous lesions and colonic 
intraepithelial neoplasia by RNA sequencing125. miR-548c-5p, miR-548i and miR-
548am-5p were found as the most differentially expressed miRNAs with regard to 
lymph node metastasis. miRNAs are correlated with molecular histological markers, 
such as Ki-67 and CD34, which is useful to determine cell proliferation and 
angiogenesis in CRC development123. Furthermore, miRNAs could be helpful in 
CRC treatment permitting also to overcome the resistance to cancer therapy126. For 
instance, miR-214 enhances CRC radiosensitivity by inhibiting autophagy in CRC 
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cells. The overexpression of miR-143 is related to the oxidative stress and cell death 
in CRC cells, which might elude resistance of CRC cells to oxaliplatin. miR-195 is 
able to desensitize CRC cells to 5-fluorouracil (5-FU). Several miRNAs are potential 
biomarkers for CRC detection124. However, no single miRNA alone has been 
identified as an ideal CRC biomarker up to now. Similarly to other gene or protein 
cancer markers, some miRNAs are predictive but not specifically for one kind of 
cancer125. For example, miR-18a is reported to be a tumor suppressor by inhibitng 
CDC42 in CRC. However, miR-18a is also a candidate biomarker for breast cancer 
and lung cancer, highly expressed in benign breast samples than normal controls and 
correlating with poor prognosis in patients with non-small cell lung cancer126. 
Similarly, miR-155 inhibits colorectal cancer progression and metastasis, while it is 










1. Analysis of TCGA Database  
 
Gene expression data and clinical information for 623 colorectal adenocarcinoma 
samples and 51 normal colonic tissues were downloaded from the TCGA database 
using the Firebrowse website. RNA-Seq by Expectation Maximization (RSEM)-
normalized data for the colon adenocarcinoma (COAD) cohort were matched with 
clinical data from the Clinical Pick Tier1 archive. B4GALNT2 mRNA expression 
was compared with stage, microsatellite stability (MS) status, response to treatment, 
histological type, and survival. Since the samples did not present a normal 
distribution of B4GALNT2 expression, non-parametric statistical tests were used. 
The Mann–Whitney test was used to analyze the difference of B4GALNT2 
expression in normal and tumor tissues of mucinous vs. non-mucinous histological 
type. The Kruskal–Wallis test was used to evaluate B4GALNT2 mRNA expression 
across cancer stages and MSS/MSI groups. Identification of highly expressed genes 
in the high and low B4GALNT2 expressers was performed through two-way 
ANOVA and Bonferroni’s multiple comparison test. 
2. OncoLnc Database 
OncoLnc is a tool for identifying survival correlations, and for downloading clinical 
data coupled to expression data for mRNAs, miRNAs, or long noncoding RNAs 
(lncRNAs)127. OncoLnc contains survival data for 8,647 patients from 21 cancer 
studies performed by The Cancer Genome Atlas (TCGA), along with RNA-SEQ 
expression for mRNAs and miRNAs from TCGA, and lncRNA expression from 
MiTranscriptome beta. OncoLnc analyses include Cox regression results as well as 
mean and median expression of each gene. For the Cox regression results, in addition 
to p-values, OncoLnc stores the rank of the correlation. The rank is calculated per 
cancer, per data type.  
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3. SMART App 
 
SMART (Shiny Methylation Analysis Resource Tool) App is a web-based tool to 
explore and interpret the DNA methylation data across 33 cancer types from TCGA. 
The SMART App integrates multi-omics and clinical data with DNA methylation 
and provides key interactive and customized functions including CpG visualization, 
pan-cancer methylation profile, differential methylation analysis, correlation 
analysis and survival analysis for users to analyze the DNA methylation in diverse 
cancer types in a multi-dimensional manner. 
 
4. CSmiRTar: Condition-Specific microRNA 
targets database 
CSmiRTar (Condition-Specific miRNA Targets) provides computationally 
predicted targets of 2588 human miRNAs from four most widely used miRNA target 
prediction databases (miRDB, TargetScan, microRNA.org and DIANA-microT) and 
implements (i) a tissue filter to search the miRNA targets expressed in a specific 
tissue, (ii) a disease filter to search the miRNA targets related to a specific disease, 
and (iii) a database filter to search the predicted miRNA targets supported by 
multiple existing databases.  
 
5. Cell Lines  
 
In this project, three main cell lines derived from colorectal cancer were used: 
LS174T (ATCC® Number: CL-188™), SW480 (ATCC® CCL-228TM) and 
SW620 (ATCC® CCL-227TM). LS 174T cells were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM), SW480 and SW620 cells were cultured in 
Leibovitz's L-15 medium, all from Microgem. The basal medium was supplemented 
with 10% fetal bovine serum (FBS), 2 mM of L-Glutamine and 100 μg/mL 
Penicillin/Streptomycin, all from Microgem. LS174T cells were kept in an incubator 
with a humidified atmosphere of 5% CO2 at 37ºC, SW480 and SW620 cells were 
kept in culture in absence of CO2 in a humidifier incubator at 37ºC while   
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The cell line LS174T was established from a stage II colorectal adenocarcinoma in 
a 58 years old Caucasian female. The cell lines SW480  and SW620 were derived 
from the primary colorectal adenocarcinoma of a 50 year old Caucasian man, Dukes 
stage B, and from its lymph node metastasis, Dukes’ type C, respectively.  
The construction of B4GALNT2 transfectants was reported previously by our 
group77. Briefly, the PCR amplification of the B4GALNT2 short form derived from 
the human colon cancer cell line Caco2 was performed using the forward primer 
L.19 (5’-CACCATGACTTCGGGCGGCTCG-3’) and the reverse primer R.10 (5’-
CCAGTAACTGAGCCATTTCCCTTTTCC-3’). The underlined sequence in the 
forward primer is required for the cloning in TOPO vectors and is not gene specific. 
The PCR product was cloned in pcDNA3.1 Directional TOPO® Expression vector 
(Invitrogen, Paisley, UK).  
LS174T cells were transfected using the calcium phosphate method with either an 
expression vector for the short form of B4GALNT2 cDNA cloned in pcDNA3 or 
with the empty vector and selected with 0.4 mg/mL G418. Resistant clones were 
isolated with cloning cylinders, expanded and screened for B4GALNT2 activity. 
The procedure generated two B4GALNT2-expressing clones S2 and S11 and the 
polyclonal negative control Neo population. B4GALNT2 enzymatic activity was 
measured as the difference between the incorporation of radioactive GalNAc on 
fetuin and the incorporation of radioactive GalNAc on  asialofetuin.  
In SW480 and SW620 cell lines FUT6 transfection was performed with a FUT6 
pcDNA.1 expression plasmid and an empty pcDNA3.1 for G418 resistance in a 10:1 
ratio. B4GALNT2 transfection was performed with the cDNA of the short form of 
B4GALNT2 cloned in pcDNA3.1 described above. Mock transfections with empty 
pcDNA.3.1 to obtain negative control Neo transfectants were set in parallel. Cells 
were selected with 1mg/mL G418. G418-resistant polyclonal populations, were 
cloned. Single clones were isolated, expanded and screened for the expression of the 
Sda or sLex antigens. For both SW480 and SW620, the following cell populations 
were used: SW480 or SW620 Neo, which are a negative control formed by mock-
transfected, G418-resistant cells; SW480 or SW620 FUT6, which are a pool of three 
clones, highly expressing FUT6 and sLex antigen; SW480 or SW620 B4GALNT2, 





6. Slot Blot Analysis of Carbohydrate Antigens  
 
Cells were collected by trypsinization and homogenized in ice cold water. The 
protein concentration of the homogenates was determined using the Lowry method. 
Thirty micrograms of protein homogenates were spotted on a nitrocellulose 
membrane in a final volume of 100 μL using a slot- blot apparatus. A wash with 150 
μl of phosphate buffer saline with 0,1% tween-20 (PBS-T) was performed in order 
to ensure the transfer of all the samples. All successive incubations were done on an 
orbital shaker. After the passage of all of the liquids underneath, the membrane was 
incubated for 1 hour at room temperature with 1% BSA in PBS, as blocking solution. 
Then 3 washes were performed, 5 minutes each, with PBS-T for 1 hour at room 
temperature with the primary antibody. Next, the membrane was washed 3 times, as 
described before, for 1 hour at room temperature with the secondary antibody. 
Membranes were washed again 3 times.  
For the B4GALNT2-transfected cells were used an anti-Sda KM694 antibody, kindly 
provided by Kyowa Hakko Kogyo Co. Ltd., Tokyo, Japan, diluted 1:2000 in BSA 
0,1% in PBS-T as primary antibody and an anti-IgM conjugated with horseradish 
peroxide, diluted 1:10000 in 0,1% BSA in PBS-T as secondary antibody. 
For the FUT6 transfection, were used an anti-sLe
x 
diluted 1:500 in BSA 0,1% in 
PBS-T as primary antibody and an anti-IgG conjugated with horseradish peroxide, 
diluted 1:10000 in 0,1% BSA in PBS-T as secondary antibody. 
 The reaction was performed using Westar ηC 2.0 from Cyanagen according to the 
manufacturer’s instructions and detected with a photographic film (Kodak). Pictures 
of the films were taken using EDAS 290 camera (Kodak). Densitometric analysis 
was performed using Kodak 1D software.  
 
7. Enzymatic activity 
 
B4GALNT2 enzyme activity was assessed as the difference between the 
incorporation of [3H]-GalNAc on fetuin and asialofetuin, as previously described by 
our group86. Briefly, the assay mixture contained in a final volume of 25μL: 80 mM 
Tris/HCl buffer, pH 7.5; 10 mM MnCl2; 0.5% Triton X-100; UDP-[
3H]GalNAc 
(ARC, St. Louis, MO) with a specific activity of 550 dpm/pmol, 2 mM ATP, 250 μg 
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of either fetuin (Sigma) or asialofetuin (prepared by the desialylation of fetuin in 50 
mM H2SO4 at 80ºC for 2 hours, followed by dialysis) as acceptors and 50-70 μg of 
protein homogenates as the enzyme source. After 3 hours incubation at 37ºC, the 
acid-insoluble radioactivity was precipitated with 1% phosphotungstic acid in 0.5 M 
HCl (FTA). Pellets were washed two times with FTA and once with methanol. 
Subsequently, the samples were boiled for 20 minutes with 1 M HCl. At the end, the 
samples were resuspended and read with the scintillation counter Guardian 1414 
Liquid Scintillation Counter (PerkinElmer) after the addition of 3.5 ml of 
scintillation liquid. 
 
8. Doubling Time Assay  
 
In 6-well plates, aliquots of 2 × 105 cells for well were seeded in duplicate. After 24 
h incubation at 37 ◦C, the cells of 2 wells were harvested and counted. This number 
of cells was considered T0. Pairs of wells were harvested and counted 48 h later 
(T48). The doubling time (DT) was calculated by using the following formula: DT 
= (48) × 0.3/Log (N°cellsT48/N°cellsT0). Statistical analysis was performed by 
using one-way analysis of variance (ANOVA) and Dunnett’s multiple comparisons 
test.  
 
9. Clonogenic Assay 
 
About 50 cells diluted in 2 mL of complete DMEM or L-15 medium were seeded in 
triplicate in 6-well plates and incubated at 37°C. After 15 days, the plates were 
washed with phosphate buffered saline (PBS) and the colonies were fixed and 
stained for one hour at room temperature with a solution containing formaldehyde 
4% and Crystal Violet 0.005% in PBS. Photographs of the wells were taken without 
magnification and the colonies visible at naked-eye were counted. Statistical analysis 
was performed using one-way ANOVA and Dunnett’s multiple comparisons test. 
 
10. Soft Agar Growth Assay  
 
One milliliter of a 0.5% agar solution in complete DMEM or L-15 was dispensed in 
each well of a six-well plate and allowed to solidify. On top of this layer of agar, 1 
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mL of a 0.3% agar solution in complete DMEM or L-15 medium containing 1 × 104 
cells per well was dispensed in triplicate. The plates were incubated for two weeks 
at 37° C in a humidified incubator. To evaluate the number of colonies formed, the 
plates were fixed and colored for one hour at room temperature with a solution 
containing formaldehyde (4%) and crystal violet (0.005%) in phosphate buffered 
saline (PBS, 20 mM phosphate buffer pH 7.5, 0.15 mM NaCl). Pictures of LS174T 
cells were taken at 4X magnification and colonies were counted. As regards SW480 
and SW620 cell photographs of the wells were taken without magnification and the 
colonies visible to the naked-eye were counted. Statistical analysis was performed 
using the non-parametric Kolmogorov–Smirnov test for LS174T cells. One-way 
ANOVA and Dunnett’s multiple comparisons test were for the statistical analysis of 
SW480 and SW620 cells. 
 
11. Tridimensional (3D) Culture  
 
10.000 cells were seeded in six-well plates whose bottoms were coated with 0.5% 
agar in complete DMEM or L-15  medium. Spheroid growth was monitored every 
2–3 days. Owing to their non-adherent condition, it was impossible to quantitate 
spheroids by counting. Thus, cells were quantitatively collected, pelleted by 
centrifugation and homogenized. The protein concentration of the homogenate was 
assessed by Lowry assay and its volume was measured. The number of cells was 
calculated using the protein concentration of a homogenate obtained from a known 
number of cells grown in standard conditions as a reference. The statistical analysis 
was performed using one-way ANOVA and Dunnett’s multiple comparisons test. 
 
12. Wound-Healing Assay  
 
The wound-healing assay was performed using Culture-Insert 2 Well (Ibidi). This 
consists in a 2 well silicone insert with a defined cell-free gap of approximately 500 
μm, which gives the possibility to plate the cells in the two wells and to evaluate 
their ability to close the wound once the insert has been removed. Aliquots of 5 × 
104 cells were seeded in each well. When the cells reached confluency, the insert 
was removed and the healing of the wound was measured by taking pictures every 
24 h with Nikon Eclipse TS100 inverted microscopy at a 4x magnification and a 
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Digital C-Mount camera Sony Colour. The area free of cells was measured using the 
MRI Wound Healing Tool of ImageJ. The statistical analysis was performed using 
two-way ANOVA and Tukey’s multiple comparisons test.  
 
13. ALDEFLUOR Assay  
 
ALDEFLUOR (Stem Cell Technologies) was activated following the 
manufacturer’s instructions and added to 5 × 105 aliquots of cells. Half of the cell 
suspension was treated with DEAB, a specific ALDH inhibitor used as a negative 
control. After 45 min at 37° C, cells were washed and suspended in ALDEFLUOR 
buffer. The fluorescent signal was acquired with a FACSCalibur flow cytometer and 
Cell Quest Pro software. On a dot plot with FL1 (green fluorescence) on the X axis 
and side scatter (SSC) on the Y axis, we set the fluorescence of the DEAB sample 
(negative control) and defined the area for ALDH-positive cells. Cells included in 
this area were considered ALDEFLUOR-positive.  
 
14. Total RNA extraction 
 
Total RNA extraction was performed according to Chomczynski & Sacchi 
method128, being suspended at the end in 50 μl of DNase/RNase free water. RNA 
was quantified using the Nano Genius Photometer ONDA, measuring the 
absorbance at 260 nm with a 2.0 ±0.5 ratio of Abs260/Abs280. RNA integrity was 
assessed running RNA samples on a 1% agarose gel. 
 
 
15. Transcriptomic Analysis  
 
Transcriptomic analysis of RNA from LS174T Neo and S2/S11 cells grown either 
in standard 2D conditions or in 3D conditions (as spheroids) and SW480 and SW620 
cells transfected with FUT6 or B4GALNT2 and their respective Neo negative 
controls was performed in duplicate using Agilent whole human genome oligo 
microarray (G4851A). Statistical analysis was performed using a moderated t-test, 
and the false discovery rate was controlled with the multiple testing correction 
Benjamini–Hochberg with Q = 0.05. Pathway analysis of differentially expressed 
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genes was determined using the web-based software MetaCore (GeneGo, Thomson 
Reuters). Gene function was studied through an extensive literature search.  
 
16. Statistical analysis  
 
The GraphPad Prism 6 software was used to perform statistical analysis, using the 







1) Identification of correlations between B4GALNT2 expression and clinical 
parameters. This was accomplished through an in silico survey of the “The 
Cancer Genome Atlas Database” (TCGA) which contains mRNA expression 
values and clinical data of hundreds of cancer specimens and normal tissues.  
2) Study of the mechanisms linking B4GALNT2/Sda expression to CRC 
phenotype.  To this scope three cell models have been transfected with 
B4GALNT2 cDNA: LS174T cell line, constitutively expressing the sLex 
antigen, in which B4GALNT2 expression leads to both Sda expression and sLex 
inhibition; SW480/SW620 pair, not expressing sLex, in which B4GALNT2 
expression leads to Sda expression but not sLex inhibition.  
3) Evaluation of the impact of sLex expression on the phenotype of colon 
cancer cells of different malignancy. It was performed through the transfection 
of SW480/SW620 pair with FUT6 cDNA. The first cell line is from a primary 
tumor, the second from a metastasis of the same patient. 
4) Analysis of the impact of glycosyltransferase expression on the 
transcriptome of colon cancer cells. This was carried out through microarray 
analysis of B4GALNT2 and FUT6 transfectants of the three cell lines.  
5) Search for a “B4GALNT2 signature” on the transcriptome common to the 
three cell lines. This was done through a bioinformatic comparison of the three 
B4GALNT2 transfectants and their respective mock-counterparts. 
6) Study of the mechanisms regulating B4GALNT2 expression in CRC. It was 
done through data mining and analysis of The Cancer Genome Atlas (TCGA) 




CHAPTER III - RESULTS 
Analysis of B4GALNT2 expression in colorectal cancer 
patients: TCGA data mining 
Note: Results presented in this section were taken from the published manuscript:  
- Pucci, Michela; Malagolini, Nadia; Dall’Olio, Fabio "Glycosyltransferase B4GALNT2 as 
a Predictor of Good Prognosis in Colon Cancer: Lessons from Databases" Int. J. Mol. Sci. 
2021, 22, 4331 
 
3.1 Clinical implications of glycosyltransferases expression 
in CRC: survey of TCGA database 
To assess the impact of glycosyltransferase expression on colon cancer progression, 
the survival probability of a TCGA cohort of colon adenocarcinoma (COAD) 
patients was analyzed as a function of the expression of glycosyltransferases relevant 
for the biosynthesis of cancer-associated carbohydrate structures. The TCGA survey 
included the following enzymes: GALNT1, GALNT8, ST6GALNAC1, C1GALT1, 
ST3GAL1, ST3GAL2, ST6GALNAC2, B3GNT6, GCNT1, ST6GALNAC6, 
MGAT3, MGAT5, FUT8, B4GALT1, B3GNT5, B3GALT5, ST3GAL3, ST3GAL4, 
ST3GAL6, ST6GAL1, ST6GAL2, FUT3, FUT4, FUT5, FUT6. In Figure 13 are 
shown the Kaplan-Meier plots relative to the survival of the patients falling in 15th 
upper percentile- 15th lower percentile of the expression of each glycosyltransferase. 
Surprisingly, only patients with higher expression of B4GALNT2 displayed a 
significant longer overall survival (Figure 13). Within the first 1000 days the two 
group of patients displayed very similar survival curves, while long-term survivals 
belonged exclusively to the high-B4GALNT2-expressers. Collectively, these data 
suggest a substantial effect of B4GALNT2 level in CRC patients, especially its 





Figure 13. Kaplan-Meier survival curves of colonadenocarcinoma patients relative to 
glycosyltransferases expression. Kaplan-Meier analysis was performed on Oncolnc 
website (http://www.oncolnc.org/) dividing patients into two groups (15th lower / 15th higher 
percentile). Logrank p-value is shown on the right bottom of each plot.  
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3.2 Oncogenes and tumor suppressor genes expression 
poorly correlates with COAD patients survival  
As shown in Figure 14, B4GALNT2 expression is a significant predictor of long 
survival in CRC TCGA cohort. To extend this observation to a more general context, 
the study investigated whether tumor suppressors and oncogenes known to play 
fundamental roles in cancer and, in particular in CRC, were better predictors of 
patients’ survival. The relationship between the high/low expression of several 
oncogenes and tumor suppressor genes and patients’ survival in the COAD TCGA 
cohort was analyzed. In Figure 14 are shown the Kaplan-Meier survival curves of 
COAD patients falling in the 15% upper or 15% lower level of expression of genes 
known to promote or suppress tumor growth and in particular COAD growth. 
Survival curves have been ordered according to the p value and boxed in red or blue 
according to the recognized role as tumor promoting or tumor suppressing activity 
of the genes. A statistically significant (p≤0.05) association with survival was shown 
by genes SMAD6, TERT, EGFR, CDKN2A, CTNNB1 and PIK3CA. Genes whose 
association with survival displayed p values 0.05≤p≤0.1 included CCNE1, SMAD2, 
CDH1, TP53 and BRAF. These data reveal that the level of expression of only a few 




Figure 14. Kaplan Meier plots of COADREAD patients according to the expression 
level of oncogenes and tumor-suppressor genes. Survival curves were created on 
OncoLnc website using the 15% high percentile (red lines) and 15% low percentile (blu 
lines) of a gene. Graphs are shown in order to the increasing p value and boxed in red or 




3.3 Clinical implications of B4GALNT2 expression in CRC: 
Survey of TCGA database 
In order to investigate the clinical implication of B4GALNT2 in CRC patients, 
TCGA survey was carried out through collection of the main clinical information of 
623 colorectal cancer patients, including age at initial diagnosis, gender 
(female/male), histological subtype of tumor (adenocarcinoma or mucinous 
adenocarcinoma), microsatellite status (microsatellite stable, high microsatellite 
instability or low microsatellite instability), stage (stage I, II, III or IV) and follow-
up treatment success (complete remission/response, partial remission/response, 
stable disease or progressive disease). Some of these clinical data were not available 
for some CRC specimen. In 51 cases gene expression data of normal colonic mucosa 
(matching samples with those of CRC) were also accessible.  
The survey of TCGA database revealed a relationship between B4GALNT2 gene 
expression and clinical parameters of CRC. As shown in Figure 15 A, the mean level 
of B4GALNT2 mRNA in CRC tissues is very low compared to normal tissues, albeit 
extremely variable. No significant correlation was found between B4GALNT2 
expression and stage or microsatellite stability status (Figure 15 B, C). However, 
B4GALNT2 expression was significantly high in the therapy responder (Figure 15 
D) and non-mucinous subtype groups (Figure 15 E). Yet, it was compared the level 
of B4GALNT2 mRNA in patients either affected or not affected by mutations in 
genes relevant for CRC carcinogenesis such as the tumor suppressor genes TP53.  
Interestingly, it was found a significant correlation between high B4GALNT2 






Figure 15. The Cancer Genome Atlas (TCGA) data. (A) Expression level of B4GALNT2 
mRNA in normal mucosa and colorectal cancer (CRC) specimens. (B–F) Expression of 
B4GALNT2 mRNA in CRC specimens grouped according to stage (B), microsatellite 
stability status (C), response to therapy (D) subtypes (E), and TP53 mutation (F). MSS: 
microsatellite stable; MSI-l: microsatellite instable-low; MSI-H: microsatellite instable-
high. * p ≤ 0.05; **** p ≤ 0.0001.   
 
 
In search of gene expression signatures associated with high or low B4GALNT2 
expression, two cohorts including the patients in the 15% upper and 15% lower 
percentiles of B4GALNT2 mRNA level were compared. Table 1 represents the 
genes statistically modulated between high and low B4GALNT2 expressers in CRC. 
 
In the cohorts of HBE and LBE the mean±SD levels of B4GALNT2 expression was 
0±0 and 367±501, respectively. 614 genes displayed a significantly different 
expression level: 451 were highly expressed in HBE; 163 genes had an opposite 
behavior. The gene expression ratio between high/low expresser ranged from 200 to 
-11. Genes showing the most remarkable changes, selected for a ratio higher than 
10.0 or lower than -4.0, have been characterized by an extensive literature search, in 
particular for their role in cancer (Table 1). A color tag was assigned to the putative 
tumor promoting- or tumor-restraining role of the change as follows: green for 
higher expression of tumor-restraining genes or lower expression of tumor-
promoting genes in HBE; vice versa for red. Only genes with a recognizable role in 
cancer were reported. High B4GALNT2 expression was associated with 27 tumor 
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restraining and 10 tumor promoting changes, suggesting its association with a low-
malignancy molecular signature. 
 
Table 1. Genes differentially modulated in high B4GALNT2 expressers (HBE) and low 
B4GALNT2 expressers (LBE)  
 
Gene Ratio Gene role PubMed 
 
CLCA1 203 
Involved in mucus secretion and as a tumor 
suppressor. Suppresses CRC malignancy. 
28974231  
ZG16 151 
Involved in protein trafficking. Sequentally 
reduced from adenoma to CRC. 
29661177  
ITLN1 62 
Lectin recognizing microbial carbohydrates. 
Protective in CRC 
31893510  
CLCA4 51 
Involved in mediating chloride conductance. 
Down-regulated genes in CRC. 
32027181  
SPINK4 48 
Serine Peptidase Inhibitor. Its down-regulation is 
associated with poor survival in CRC. 
31888570  
CA1 45 




Involved in transcriptional regulation, acts as an 
oncogene in some cancers. 
30509089  
PYY 33 
Inhibitis intestinal mobility. Decreased expression 
is associated with CRC. 
11825654  
GUCA2B 32 
Regulator of intestinal fluid transport. Tumor 
suppressor in CRC. 
29788743  
CA4 27 
Stimulates the ion transporter activity of SLC4A4. 
Predictive biomarker in CRC. 
32031891  
MS4A12 25 
Involved in signal transduction. Promotes 
malignant progression in CRC. 
18451174  
BEST2 23 
Anion channel. Methylation marker for early 
detection and prognosis of CRC. 
22496748  
HEPACAM2 23 
Required for centrosome maturation. Associated 
with good prognosis. 
29659199  
TMIGD1 22 
Controls cell-cell adhesion and proliferation. 
Tumor suppressor in CRC. 
33129760  
CLDN8 16 
Claudin 8. Component of tight junctions. Down-
regulated in CRC 
21479352  
B3GNT6 14 
Synthesizes core 3 O-linked chains. Down-
regulation associated with malignancy in CRC 
28745318  
KIF19 13 
Microtubule-dependent motor protein. Higher 
expression associated with longer survival 
28901309  
CSAG2 13 
Chondrosarcoma-Associated Gene 2/3 Protein. 
Necessary for tumorigenesis. 
32761762  
FCGBP 12 
Maintens of the mucosal structure. High 
expression is associated with better prognosis 
31268166  
CDKN2BAS 12 
CDKN2B Antisense RNA 1. Promotes 
progression of ovarian cancer 
32572907  
REG1B 11 
Regenerating Islet-Derived Protein 1-β. Its 
silencing inhibits CRC growth. 
25768000  
IGJ 11 
Joining Chain Of Multimeric IgA And IgM. 
Down-regulated in CRC 
31749922  
LEFTY2 10 
Member of the TGF-β superfamily. Negative 
regulator of endometrial cell proliferation. 
27497669  
FUT5 10 






Secreted mucus forming mucin. Suppresses CRC 
migration and metastasis. 
28725043  
PLIN1 -4 
Modulator of adipocyte lipid metabolism. Inhibits 
breast cancer cell proliferation. 
27359054  
PCP4 -4 
Functions as a modulator of calcium-binding by 
calmodulin. Anti-apoptotic peptide. 
25153723  
IGF2 -4 
Possess growth-promoting activity. 
Overexpression is associated with poor prognosis. 
24080445  
SLC14A1 -4 Urea channel. Cancer stem cell marker. 29329541  
FREM1 -5 
Extracellular matrix protein. Associated with 
better prognosis in bladder cancer. 
33058542  
CASQ2 -5 
Calsequestrin. High expression associated with 
poor survival in bladder cancer. 
31991631  
CPLX2 -6 
Involved in exocytosis. Associated with poor 
prognosis in lung tumors. 
3912489  
ADIPOQ -6 
Adiponectin. Anti-inflammatory adipokine. 
Lower expression in CRC. 
27061803  
WIF1 -7 
Inhibits WNT actvities. Hypermethylation is 
associated with a favorable clinical outcome. 
31830937  
CHRNB2 -9 
Cholinergic Receptor Nicotinic Beta 2 Subunit. 
Down-regulated in gastric cancer. 
30175534  
AP3B2 -10 
Involved in protein sorting. Low expression is 
associated with long survival in rectal cancer. 
29050227  
TSIX -11 
XIST Antisense RNA. Dysregulates cancer 
pathways in multiple tumor contexts. 
29617668  
 
Genes differentially modulated in HBE and LBE cohorts were analyzed by the false 
discovery rate two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli. Only 
genes showing up-regulation ≥10 or down-regulation ≤-4 and with a recognized role in 
cancer are reported. “Ratio” refers to the HBE/LBE ratio. When the expression was higher 
in LBE, the HBE/LBE ratio was expressed preceded by a “minus” sign. The role of the gene 
was deduced from Genecards website. The red or green labels indicate putative tumor-
promoting or tumor-restraining changes, respectively.  
 
 
To establish the prognostic potential of genes modulated with respect to B4GALNT2, 
the survival curves of the 15 top highly expressed genes and the 10 less expressed 
genes in HBE were obtained (Figure 16). The predictive potential of the highly 
regulated genes was very good, while genes poorly expressed in HBE lacked any 
association with prognosis. In particular, the Kaplan-Meier curves of the 15 highly 
regulated genes (A) were relatively similar, with strong expresser patients displaying 
a more or less pronounced tendency to better prognosis (the red curve is always 
above the blue curve). Four genes (ZG16, ITLN1, BEST2 and GUCA2B) displayed a 
statistically significant relationship. The significance of ZG16, a gene previously 
shown to be associated with good prognosis in CRC, was particularly high. The p 
value of these genes was always lower than 0.5. On the other hand, genes poorly 





Figure 16. Kaplan-Meier survival curves of patients expressing different levels of genes 
in LBE and HBE cohorts. Curves were generated using the 15% higher (red lines) and 
15% lower expressers (blue lines) of the indicated genes. A: 15 top highly up-regulated 






3.4 Several glycogenes are differentially modulated in HBE 
and LBE. 
 
In LBE and HBE groups the expression of genes involved in the biosynthesis and 
recognition of glycans, as well as heavily glycosylated glycoproteins, such as 
mucins, and sugar binding proteins, such as galectins, appears significantly different. 
Table 2 shows the expression level of glycogenes differentially modulated in LBE 
and HBE. These genes encode proteins involved in: first steps of O-glycans 
biosynthesis (GALNT8, B3GNT6, ST6GALNAC1, ST6GALNAC2); ganglioside 
production (ST6GALNAC6); proteoglycan synthesis (B3GNT7); synthesis of sialyl 
Lewis antigens (B3GALT5, ST3GAL4, FUT5); terminal galactose recognition 
(LGALS4, LGALS9B). Four genes encode O-glycoproteins (MUC1, MUC2, MUC4, 
MUC5B). Only two genes (ST6GAL1, ST6GAL2) that codify enzymes responsible 























Table 2. Expression level of glycogenes in HBE and LBE. 
 
 
“Ratio” indicates the ratio between gene expression in HBE/LBE. When the expression was 
higher in LBE, the HBE/LBE ratio was expressed with “minus” sign.  
 
 
3.5 Methylation partially controls the expression of 
B4GALNT2  
 
To elucidate mechanisms regulating B4GALNT2 expression, gene methylation was 
investigated in colorectal cancer patients through the SMART (Shiny Methylation 
Analysis Resource Tool) App, a web-based tool that allows a comprehensive 
analysis of DNA methylation data of TCGA project. 
The segment plot in Figure 17A shows the CpGs associated to B4GALNT2 gene and 
their genomic locations along with transcripts. Genomic sites covered by the 
methylation probes include the CpG island as well as a Northern shore (N-shore, 
upstream the island), a Southern shore (S-shore, downstream the island) and an 
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intronic (open-sea) site located between exons 6 and 7. Differential analysis of tumor 
and normal samples revealed that methylation in both the N-shore and S-shore was 
never statistically different between normal and tumor tissues, although in the latter 
the methylation level was more heterogeneous among patients (Figure 17B). On the 
other hand, in both normal and the vast majority of cancer tissues the extent of 
methylation was very low in seven locations within the island (cg01147550-
cg18208707 and cg02445664). In the same region positions cg20233029 and 
cg03167683 displayed a small but significantly reduced methylation in tumor 
tissues. The “open sea” site cg043380107, located at the intron, displayed a highly 
significant and very heterogeneous methylation decrease in cancer. Correlation 
analysis of B4GALNT2 expression with methylation status of the 16 sites in tumor 
tissues (Figure 17C) indicated that in some cases methylation results in 
enhancement, rather than inhibition, of gene expression. Indeed, methylation of the 
intronic site cg043380107 is associated with increased, rather than decreased, 
B4GALNT2 expression. Exception for the first two sites in the N-shore, in all the 
remaining sites low methylation is required for high B4GALNT2 expression, 
although many samples displaying very low methylation failed to express 
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Figure 17. DNA methylation of B4GALNT2 promoter region. A: segment plot 
highlighting the promoter region and coding exons of the B4GALNT2 gene. The 
approximate position of the probes is indicated. B: Methylation level of the different probes. 
*p<0.05; ***p<=0.001; ****p<0.0001. C: Correlation between B4GALNT2 expression 
level and methylation of specific positions in tumor tissues. 
 
 
3.6 miR-204-5p regulates B4GALNT2 expression in CRC 
 
Gene expression can be post-transcriptionally regulated by microRNAs (miRNAs), 
small non-coding RNAs of ~22nt, through suppressing mRNA translation or 
inducing mRNA degradation. Thus, the potential role of miRNAs in the regulation 
of B4GALNT2 expression was investigated. Interrogation of CSmiRTar database 
that integrates miRNA-target interactions and their functional roles in various 
biological processes provided a list of miRNA potentially targeting B4GALNT2 in 
colorectal cancer. The study considered only miRNA supported by at least two of 
the four miRNA target prediction databases and with a “normalized miRNA score, 
NMR” >0.2 (Figure 18A). To understand the role of these miRNA on B4GALNT2 
expression, their mean expression level was determined in the LBE and HBE groups. 
In consideration of the lower number of miRNA data available for TCGA patients, 
LBE and HBE subjects expressing a level of B4GALNT2 mRNA lower or higher 
than 20 were considered, respectively. Among miRNAs targeting B4GALNT2, five 
displayed little and non-significant differences between the two groups while miR-
204-5p was 2.7 fold less expressed in HBE than in LBE (p=0.01) (Figure 18A). 
Correlation analysis of B4GALNT2 with single miRNAs expression (Figure 18B) 
revealed that miR-204-5p was not expressed in all the HBE patients, although 

























































Expression of miRNA potentially targeting B4GALNT2 in LBE and HBE cohorts  
     miRNA       Mean NMS*               LBE  HBE    LBE/HBE Ratio  p*  
hsa-miR-105-5p  0.664   23.2  24.7  0.9                0.43 
hsa-miR-145-5p  0.652   2146  2022    1.1   0.37 
hsa-miR-204-5p 0.594   9.7  3.6  2.7   0.01 
hsa-miR-150-3p  0.449   2.4  2.5  0.97   0.31 
hsa-miR-146b-3p  0.289    62.3  65.1  0.96   0.32 
hsa-miR-134-5p  0.272   312  289   1.1   0.1 
*NMS: Normalized miRNA score. Numbers represent the mean value reported in at least 2. Only miRNA 
with NMS> 0.2 were reported. LBE and HBE represent the expression of the miRNA in the LBE (B4GALNT2 
expression <20) or HBE (B4GALNT2 expression >20) cohorts. The only significantly modulated miRNA is 
indicated in bold. * Student’s t test for independent samples. 
A
B
Figure 18. Correlation between B4GALNT2 and miRNA expression. A: miRNA 
potentially targeting B4GALNT2 obtained from CSmiRTar database. Only miRNA 
supported by at least two of the four miRNA prediction target databases and with a 
“normalized miRNA score, NMR” >0.2 were considered. B: correlation dot plots of 





CHAPTER IV - RESULTS 
Transcriptomic and phenotypic impact of B4GALNT2 
expression in LS174T CRC cells 
Note: Results presented in this section were taken from the published manuscript:  
- Pucci M.; Gomes Ferreira I.; Orlandani M.; Malagolini N.; Ferracin M.; Dall'Olio F., “High 
Expression of the Sda Synthase B4GALNT2 Associates with Good Prognosis and 
Attenuates Stemness in Colon Cancer”, CELLS, 2020, 9, pp. 1 - 18 
 
 
4.1 Phenotypic impact of B4GALNT2 expression on colon 
cancer cells 
 
Data in clinical setting revealed a clear association between high B4GALNT2 and 
better prognosis. Thus, aiming at investigating the impact of B4GALNT2 expression 
on the malignant phenotype in vitro, in particular as a function of sLex expression, 
the colorectal cancer cell line LS174T was employed as a model due to the negligible 
levels of B4GALNT2 and good levels of the sLex antigen. LS174T cells have been 
either transfected with the short form of B4GALNT2 or mock-transfected. The three 
cell lines analyzed were Neo - a polyclonal population of mock-transfectants - and 
S2 and S11, two B4GALNT2-transfected clones. As shown in Figure 19A, the level 
of B4GALNT2 mRNA and enzyme activity in mock transfectants was nearly 
undetectable, while it was high in S2 and S11 clones. In S2 and S11 clones, but not 
in Neo cells, the Sda antigen was strongly expressed on high-molecular-weight 
proteins (Figure 19B). On the other hand, the sLex antigen, which is also carried by 
high-molecular-weight proteins, was more strongly expressed by Neo cells than by 
S2 and S11 clones (Figure 19B). This is due to the previously documented 






Figure 19. Biochemical characterization of B4GALNT2-transfected cell lines. A: The 
enzymatic activity (dark gray) of Neo cells and B4GALNT2-transfected clones S2 and S11 
was measured as the difference between the incorporation of radioactive GalNAc on fetuin 
and asialofetuin. The mRNA (light gray) was measured by real-time RT-PCR and 
normalized with β-actin/GAPDH. B: Western blot analysis of Neo cells and B4GALNT2-
transfected clones with anti Sda (left) and anti sLex (right) antibodies, revealing a partial 
replacement of the sLex antigen with the Sda. 
 
 
The LS174T Neo and B4GALNT2 transfected cells  were analyzed for the following 
typical aspects of malignant growth: 
 
 ANCORAGE INDEPENDENT GROWTH IN SOFT AGAR 
 
LS174T cells were evaluated for their ability to form colonies by a soft agar colony 
formation assay. This anchorage-independent growth assay is a well-established 
method for characterizing the ability of transformed cells to grow independently of 
a solid surface, and is a hallmark of carcinogenesis129.  
The rationale behind this technique is that normal and often cancer cells depend on 
contact with the extracellular matrix to grow and divide. Conversely, a proportion of 
a cancer cell population is not dependent on adhesion to extracellular matrix to grow 
and divide. Therefore, cancer cells able to form colonies in a semi-solid medium are 
considered particularly malignant129. In this assay, the cells were plated as a single 
cell within a layer of agar. Compared with mock-transfected Neo cells, S2 and S11 
clones displayed a strongly reduced ability to grow in a semi-solid medium (Figure 





 3D TUMOR SPHEROIDS  
 
LS174T cells were evaluated for their capacity to form spheroids. 3D tumor 
spheroids are self-assembled cultures of tumor cells formed in conditions where cell-
cell interactions predominate over cell-substrate interactions. Multi- cellular tumor 
spheroids resemble avascular tumor nodules, micro-metastases, or the intervascular 
regions of large solid tumors with respect to their morphological features, 
microenvironment, volume growth kinetics and gradients of nutrient distribution, 
oxygen concentration, cell proliferation and drug access130. LS174T B4GALNT2-
expressing clones were compared to Neo cells for their capacity to survive and grow 
in these harsh conditions. B4GALNT2 clones displayed a 60% reduction in ability 
to grow as spheroids in a completely liquid medium (Figure 20 B).  
 
 CLONOGENIC ASSAY OF CELLS IN VITRO  
 
LS174T cells were analyzed for their ability to grow into a colony from a single cell 
in standard growth conditions (with adhesion to a solid substrate). This assay 
essentially tests every cell in the population for its ability to undergo ‘‘unlimited’’ 
division131. It was performed by seeding 50 Neo, S2, or S11 cells in standard 
conditions. After 15 days the number of growing colonies was similar in Neo cells 
and B4GALNT2 clones (Figure 20 C).  
 
 WOUND HEALING ASSAY  
 
To evaluate whether the B4GALNT2 expression could modify the ability of cells to 
proliferate and migrate (an important feature associated with malignant 
transformation132), wound healing assay was performed with LS174T Neo 
population and S2/S11 clones. It was observed that the capacity to heal a scratch 




 ALDEFLUOR ASSAY  
 
The study of the phenotype in vitro revealed that B4GALNT2 expression leads to a 
dramatic inhibition of the ability to grow in poor or no adherence, pointing to a 
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specific effect of B4GALNT2 in regulating this property. The ability to survive and 
proliferate without the intracellular signals generated by the mechanosensors is 
documented to be intimately associated with stemness. 
To investigate the relationship between B4GALNT2 expression and stemness, the 
three LS174T cell lines were analyzed for the expression of aldehyde dehydrogenase 
(ALDH), reported to be a stem-cell and cancer-initiating cell marker in many tissues, 
including colon tissue108. 
In a typical experiment (Figure 20 E), cells were incubated with the ALDH substrate 
ALDEFLUOR, either in the presence or in the absence of DEAB (a specific ALDH 
inhibitor) to provide a negative control. While the percentage of ALDH-positive 
cells in LS174T Neo was about 40%, it was around 30% in the two B4GALNT2 








Figure 20. Phenotypic characterization of B4GALNT2-expressing cells and mock-
transfectants. A: Growth in 0.33% soft agar. Photographs were taken without magnification 
and the colonies visible to the naked-eye were counted. B: Spheroids formation assay. The 
aspect of the spheroid is shown. The total amount of protein was calculated and taken as a 
measure of the cells grown in 3D conditions. C: Colony formation assay in standard 
conditions of growth. D: Wound healing assay. The free area of the wound was quantitated 
by ImageJ and normalized to the free area of the same cell line at 0 h, which was taken as 
100%. Graphs report the quantification of the healing process at each time point. The 
microphotographs were taken at a 4x magnification. E: ALDEFLUOR assay. Cells were 
incubated with ALDEFLUOR either in the presence or in the absence of the inhibitor N,N-
diethylaminobenzaldehyde (DEAB). Gates excluding all of the cells labelled in the presence 
of DEAB were set. Cells included in the gate in the absence of DEAB, were considered to 
be ALDH positive. Histograms report the percentage of ALDH positive cells ±SD. All 
experiments were repeated at least three times. *p≤0.05, **p≤0.01, *** p≤0.001. 
 
 
4.2 Impact of B4GALNT2 expression on the transcriptome 
of LS174T colon cancer cells 
 
To understand the origin of the dramatic effect of B4GALNT2 on the phenotype of 
LS174T cells and, in particular, on the ability to grow in non-adherent conditions, 
the impact of B4GALNT2 and of 3D growth in liquid medium on the transcriptome 
of LS174T cells was investigated by microarray analysis.   
RNA preparation and analysis of the Neo population and S2/S11 clones grown in 
standard conditions or as 3D spheroids was performed in duplicate. Using 
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microarray technology, the mean level of B4GALNT2 expression was found to be 3 
in Neo and 230 in S2/S11 cells. Figure 21A illustrates a heat-map graph that reports 
the modulation of 142 genes showing a fold change ≥ 2 in LS174T S2 and S11, 
compared with Neo cells, grown in standard conditions. Panel B in Figure 21 shows 






Figure 21. Heatmaps of gene expression analysis. A: B4GALNT2-expressing and control 
Neo LS174T cells grown in standard 2 D conditions. B: Cells grown in 3D conditions or in 
standard 2D conditions. The genes that are differentially expressed are reported. Genes 
(columns) and samples (rows) were grouped by hierarchical clustering (Manhattan 
correlation). High- and low- expression was normalized to the average expression across all 
samples. Differences were analyzed by the moderated t-test. Corrected p-value cut-off: 0.15; 
multiple test correction used: Benjamini-Hochberg. 
 
The most relevant pathways modulated by B4GALNT2 in LS174T cells identified 
by GeneGo Metacore analysis are shown in Table 3. The expression of the 
glycosyltransferase affects mainly the stem cell pathways, blood coagulation, main 
growth factor signaling cascades, cell adhesion, cytoskeleton remodeling and G 









Table 3. Networks and Networks objects modulated by B4GALNT2 expression in 
LS174T transfectants.  
 
Networks Networks Objects 
Stem cell pathways SOX2, FGFR3, HEY2, IGF1, c-Kit, 
MEF2C, MLRC, MyHc 
Blood coagulation MyHC, Coagulation factor V, PAR1 
Main growth factor signaling cascades FGFR3, IGF-1 
Chemoresistance pathways c-Kit, IGF-1 
Cell adhesion Nidogen, IGF-1, MyHC, MRLC 
Cytoskeleton remodeling MyHC, MRLC 
G protein-coupled receptors signaling G_(i)-specific peptide GPCRs, G_(q)-
specific peptide GPCRs 
Pathway map visualization was performed using MetaCore pathway analysis by GeneGo. 
 
To restrict the study to the most biologically relevant genes, a more in-depth analysis 
revealed 25 genes to be modulated by B4GALNT2 by a fold change ≥ 4 (Table 4). 
Among these genes, four displayed up-regulation (CD200, NGFRAP1, 
SKAP1,SLC14A1) and 21 displayed down-regulation (FAM26F, FAM110B, ALX1, 
F5, NMT, MYH3, MBOAT2, ROR1, RAI1, FMO3, PEG10, NINL, ARMC4, MID2, 
SOX2 28, LGALS2, NPTX, GALC, STARD3NL, ZNF22, NID1). In the Table 4 each 
gene was associated to its function in cancer by functional annotation. It was also 
attributed a cancer-promoting activity or a cancer-restraining activity to many of the 
modulated genes through an intense search in literature. In addition, a violet or 
yellow label was assigned on the basis of the putative tumor-promoting or tumor-
restraining change (violet for up-regulation of tumor-promoting or down-regulation 
of tumor-restraining genes and vice versa for the yellow label). 
As highlighted in Table 4 by the label color, only three changes were putatively 









Table 4. Genes highly modulated by B4GALNT2 in LS174T cells. 
 
 
Corrected p value was calculated using the multiple test correction Benjamini-Hochberg. 
p<0.05, fold change mean S2/S11 B4GALNT2 vs Neo ≥4. The red line separates up-
Neo S2/S11
CD200 2 27,0 16,8 0,0411 CD200 molecule
Possible colon cancer stem cell 
marker
27574016
NGFRAP1 39 456,3 11,6 0,0383
nerve growth factor receptor 
(TNFRSF16) associated protein 1
Overexpression inhibits growth 
of breast tumor xenografts.
26408910
SKAP1 138 912,3 6,6 0,0231
src kinase associated phosphoprotein 
1
Modulates TCR signaling. 18320039
SLC14A1 2 10,8 5,2 0,0360
solute carrier family 14 (urea 
transporter), member 1 (Kidd blood 
group)
Potential tumor suppressor in 
lung cancer
22223368
FAM26F 8 2,0 -4,1 0,0195
family with sequence similarity 26, 
member F
Little or no information
FAM110B 9 2,1 -4,5 0,0142
family with sequence similarity 110, 
member B
Promotes growth of prostate 
cancer cells
21919029
ALX1 12 2,6 -4,6 0,0167 ALX homeobox 1
Promotes EMT and invasion in 
ovarian and lung cancer. 
26722397   
23288509
F5 12 2,6 -4,7 0,0331
coagulation factor V (proaccelerin, 
labile factor)
Little or no information
INMT 9 1,8 -4,7 0,0142 indolethylamine N-methyltransferase
Negatively associated with 
prostate cancer progression
22075945
MYH3 1198 238,9 -5,0 0,0167
myosin, heavy chain 3, skeletal 
muscle, embryonic
Little or no information
MBOAT2 14 2,5 -5,4 0,0383
membrane bound O-acyltransferase 
domain containing 2
Little or no information
ROR1 12 1,8 -6,4 0,0163
receptor tyrosine kinase-like orphan 
receptor 1
Associated with ovarian cancer 
stem cells
25411317
RAI14 51 7,7 -6,6 0,0190 retinoic acid induced 14
Overexpressed in gastric cancer, 
associated with worse 
prognosis.
29654694
FMO3 14 1,8 -7,7 0,0253 flavin containing monooxygenase 3
Involved in de-toxification of 
drugs.
16800822
PEG10 44 5,3 -8,4 0,0233 paternally expressed 10
Enhances cell invasion by 
upregulating β-catenin, MMP-2 
and MMP-9
25199998
NINL 244 28,4 -8,6 0,0339 ninein-like
High expression associates with 
poor prognosis in prostate 
cancer
30637711
ARMC4 15 1,7 -8,7 0,0196 armadillo repeat containing 4
Can be mutated in gastric 
cancer.
26330360
MID2 32 2,1 -15,0 0,0152 midline 2
In breast cancer associates with 
BRCA1 and promotes growth.
26791755
SOX2 28 1,7 -16,5 0,0163 SRY (sex determining region Y)-box 2
Associated with motility and a 




LGALS2 362 21,5 -16,8 0,0142 lectin, galactoside-binding, soluble, 2
Elevated in plasma of CRC 
patients. Promotes adhesion to 
endothelia.
21933892
NPTX1 42 2,4 -17,3 0,0123 neuronal pentraxin I
Anti proliferative in colon 
cancer
29345391
GALC 49 2,0 -24,9 0,0077 galactosylceramidase Unclear
STARD3NL 98 3,6 -27,4 0,0346 STARD3 N-terminal like Little or no information
ZNF22 83 1,9 -44,6 0,0077 zinc finger protein 22 Little or no information
NID1 459 5,1 -89,4 0,0306 nidogen 1
Promotes EMT and metastasis 
in ovarian, breast and lung 
cancer. 













GeneName Function in cancer PMID
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regulated genes from down-regulated genes. The violet or yellow labels indicate putative 
tumor-promoting or tumor-restraining changes, respectively. 
Yet, the investigation intended to examine whether those genes that were found to 
be up-regulated in LS174T S2 and S11 cells were also up-regulated in patients 
showing high B4GALNT2 levels in cancer tissues and vice versa for genes 
displaying down-regulation in S2/S11 cells. To this aim, it was considered the same 
cohorts of patients shown in Figure 14, comprising 15% of non-expressers and 15% 
of high expressers. For the 25 genes showing modulation by B4GALNT2 reported 
in Table 4, it was determined the mean level of expression in the non-expressers and 
in the high-expressers cohorts, respectively (Table 5), from TCGA. Out of the 25 
genes, one was not expressed (SLC4A1); 13 showed a difference between non-
expressers and high-expressers, consistent with the hypothesized role of 
B4GALNT2 in regulating gene expression (CD200, NGFRAP1, FAM110B, F5, 
INMT, MYH3, RAI14, FMO3, NINL,SOX2, NPTX1, STARD3NL, NID1); for six 























Table 5. Gene expression comparison between TCGA cohort (Non- and High- 
B4GALNT2 expressers and microarray analysis of LS174T cells (S2/S11 comparison 
with Neo).   
 
 
The cohorts of non-expressers (Mean ± SD =0±0) and high-expressers (Mean ± SD 367±69) 
represent the 15% lower and higher percentiles of the TCGA cohort. The column 
“Consistency” indicates whether the difference in gene expression of no- or high 
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B4GALNT2 expressers was consistent with that observed by microarray analysis of LS174T 
model. Genes showing statistically significant consistent difference are indicated in bold 




4.3 B4GALNT2 expression regulates the transcriptional 
response to 3D culture 
 
Owing to the markedly reduced ability to adapt to non-adherent growth displayed by 
B4GALNT2-expressing cells, the research focused on which genes were modulated 
by 3D culture in LS174T cells and which genes displayed a differential response to 
3D culture conditions in B4GALNT2-expressing cells S2/S11. Many genes were 
modulated by 3D culture conditions, regardless of B4GALNT2 expression. Among 

























Table 6. Genes highly modulated by 3D culture in LS174T cells.  
 










ATP4A 2 31 13,5 0,0020  ATPase, H+/K+ exchanging, alpha polypeptide
Catalyzes the hydrolysis of ATP coupled with the 
exchange of H(+) and K(+) through the plasma 
membrane
NDUFA4L2 357 4056 11,4 0,0016
 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
Respiratory electron transport
ANGPTL4 42 428 10,1 0,0010  angiopoietin-like 4, transcript variant 1
Regulates glucose homeostasis, lipid 
metabolism, and insulin sensitivity
OLAH 4 39 10,1 0,0055  oleoyl-ACP hydrolase, transcript variant 2
Contributes to the release of free fatty acids 
from fatty acid synthase
CA9 803 5805 7,2 0,0004  carbonic anhydrase IX Hypoxia response
CHGA 5 28 5,3 0,0023  chromogranin A (parathyroid secretory protein 1)
Precursor of vasostatin, pancreastatin, and 
parastatin
PPP1R3G 47 238 5,1 0,0008  protein phosphatase 1, regulatory subunit 3G
Involved in the regulation of hepatic 
glycogenesis
LCN15 15459 77132 5,0 0,0028  lipocalin 15
Transporter of glucose and other small 
molecules
PFKFB4 734 3649 5,0 0,0003
 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4
Induced by hypoxia. Involved in glycolysis
ALDOC 1145 5455 4,8 0,0004  aldolase C, fructose-bisphosphate Glycolytic enzyme
LIPF 3 15 4,6 0,0214  lipase, gastric, transcript variant 2
Involved in the digestion of dietary triglycerides
FABP1 2585 11605 4,5 0,0107  fatty acid binding protein 1, liver Binds fatty acids and other hydrophobic ligands
PGM1 1472 6277 4,3 0,0215  phosphoglucomutase 1, transcript variant 1 Glycolytic enzyme
EGLN3 135 563 4,2 0,0002  egl-9 family hypoxia-inducible factor 3
Induced by hypoxia. Adds hydroxyl groups on 
prolyl residues of HIF-1alpha
PGK1 17615 70132 4,0 0,0013  phosphoglycerate kinase 1 Glycolytic enzyme
INSM1 3 37 11,4 0,0048  insulinoma-associated 1 Transcriptional repressor
MEX3B 4 16 4,5 0,0071  mex-3 RNA binding family member B
May be involved in post-transcriptional 
regulatory mechanisms
WT1 109 443 4,0 0,0011  Wilms tumor 1, transcript variant D Transcription factor. Tumor suppressor
GLI1 95 23 -4,1 0,0033  GLI family zinc finger 1, transcript variant 1 Transcriptional activator
TCEANC 23 6 -4,1 0,0282
 transcription elongation factor A (SII) N-terminal and 
central domain containing, transcript variant 2
Transcription regulation
RUNX2 32 7 -4,4 0,0055  runt-related transcription factor 2, transcript variant 1 Transcription factor
BARX1 9 2 -4,5 0,0002  BARX homeobox 1 Homeobox transcription factor
EGR2 57 10 -5,8 0,0005  early growth response 2, transcript variant 1 Transcription factor
HOXC9 23 3 -8,2 0,0082  homeobox C9 Homeobox transcription factor
FOS 13400 1163 -11,5 0,0013  FBJ murine osteosarcoma viral oncogene homolog Transcription factor
TCF4 173 12 -14,0 0,0024  transcription factor 4, transcript variant 2 Transcription factor
EGR1 19510 1167 -16,7 0,0002  early growth response 1
Transcriptional regulator. Mediates response to 
hypoxia.
EGR3 57 3 -19,6 0,0027  early growth response 3, transcript variant 1 Transcriptional regulator.
FOSB 2295 114 -20,2 0,0002  FBJ murine osteosarcoma viral oncogene homolog B Transcription factor
NPSR1 25 252 10,2 0,0071  neuropeptide S receptor 1, transcript variant 2 G-protein coupled receptor
GPR133 3 17 6,5 0,0022  G protein-coupled receptor 133
Orphan membrane receptor. Transduces 
intracellular signals
P2RY6 3 19 6,3 0,0051  pyrimidinergic receptor P2Y, G-protein coupled
G-protein-coupled receptor that responds to 
extracellular purine and pyrimidine nucleotides
NPSR1 96 570 5,9 0,0179  neuropeptide S receptor 1 G-proteins coupled receptor
KIT 1318 7499 5,7 0,0021
 v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog, transcript variant 1
Receptor tyrosine kinase. Activates multiple 
signaling pathways
DKK1 95 424 4,5 0,0099  dickkopf WNT signaling pathway inhibitor 1 Inhibits beta-catenin-dependent Wnt signaling
HTR1D 6 25 4,2 0,0289
 5-hydroxytryptamine (serotonin) receptor 1D, G 
protein-coupled
G-protein coupled receptor for  serotonin
ADORA2A 3 12 4,1 0,0184  adenosine A2a receptor
Adenosine receptor mediated by G proteins 
activating adenylyl cyclase
GAL 107 423 4,0 0,0081  galanin/GMAP prepropeptide
Ligand of G-protein coupled receptors, involved 
in smooth muscle contraction
TGFB2 12 3 -4,0 0,0143  transforming growth factor, beta 2, transcript variant 2 Involved in many cellular processes
TAC4 24 6 -4,0 0,0061  tachykinin 4 (hemokinin) Neurotransmitter
TAS2R46 14 3 -4,3 0,0124  taste receptor, type 2, member 46
May play a role in sensing the composition of the 
gastrointestinal content. G protein coupled 
receptor
OR51E2 19 4 -4,8 0,0113  olfactory receptor, family 51, subfamily E, member 2 G-protein-coupled olfactory receptor
RTP3 93 13 -7,3 0,0064  receptor (chemosensory) transporter protein 3 Intracellular transporter
FGD5 5 41 7,7 0,0022  FYVE, RhoGEF and PH domain containing 5
May play a role in regulating the actin 
cytoskeleton and cell shape.
KIF19 67 302 4,5 0,0030  kinesin family member 19 Microtubule-dependent motor protein
CFAP74 7 2 -4,1 0,0012 cilia and flagella associated protein 74 Plays a role in cilium movement
CFAP58 8 2 -4,4 0,0007 cilia and flagella associated protein 58 Plays a role in cilium movement
GSN 11 2 -4,7 0,0087 gelsolin
Plays a role in actin polimerization. Plays a role 
in ciliogenesis
SLIT1 18 4 -5,0 0,0047  slit homolog 1 (Drosophila) Molecular guidance cue in cellular migration
PHACTR3 9 2 -5,1 0,0040  phosphatase and actin regulator 3, transcript variant 1 Actin binding
CLMN 13 2 -5,5 0,0051  calmin (calponin-like, transmembrane) Actin binding
AKR1B15 213 2803 13,1 0,0001  aldo-keto reductase family 1, member B15
NADPH-dependent reductase acting on various 
aromatic and non aromatic compounds
AKR1B10 351 4503 12,8 0,0001  aldo-keto reductase family 1, member B10
NADPH-dependent reductase acting on various 
aromatic and non aromatic compounds
AKR1C1 923 7236 7,8 0,0001  aldo-keto reductase family 1, member C1
NADPH-dependent reductase acting on various 
aromatic and non aromatic compounds
CYP1A1 252 2141 8,5 0,0003  cytochrome P450, family 1, subfamily A, polypeptide 1 
Detoxification and synthesis of cholesterol, 
steroids and other lipids
CYP1A2 193 911 4,7 0,0010  cytochrome P450, family 1, subfamily A, polypeptide 2 
Detoxification and synthesis of cholesterol, 
steroids and other lipids
MT1H 994 139 -7,1 0,0020  metallothionein 1H
Binds heavy metals. Protects from metals and 
free radicals toxicity
MT1F 4249 955 -4,4 0,0015  metallothionein 1F
Binds heavy metals. Protects from metals and 
free radicals toxicity
IL37 54 793 14,7 0,0026  interleukin 37, transcript variant 1
Suppressor of inflammatory and immune 
responses
DMBT1 3 28 8,4 0,0020
 deleted in malignant brain tumors 1, transcript variant 
2
Putative tumor suppressor. May play roles in 
mucosal defense system and cellular immune 
defense
IL36G 3 20 5,8 0,0039  interleukin 36, gamma, transcript variant 1 Member of the interleukin 1 cytokine family
CCL20 37 198 5,3 0,0011  chemokine (C-C motif) ligand 20, transcript variant 1 Chemotactic for lymphocytes
FAM19A2 41 178 4,3 0,0131
 family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A2
Neurotrophic factor involved in neuronal 
survival
ULBP1 43 8 -5,7 0,0054  UL16 binding protein 1 Ligand of a Natural Killer cells receptor




























































Corrected p value was calculated using the multiple test correction Benjamini-Hochberg (p 




SLC7A14 6 47 7,5 0,0237  solute carrier family 7, member 14 Aminoacid transporter
STC1 2 11 4,6 0,0122  stanniocalcin 1
May play a role in the regulation of intestinal 
calcium and phosphate transport
TCAF2 15 62 4,2 0,0014  family with sequence similarity 115, member C
Negative regulator of the plasma membrane 
cation channel
KCNIP4 12 53 4,4 0,0275  Kv channel interacting protein 4, transcript variant 5 Potassium channel
KCNG1 282 57 -4,9 0,0006
 potassium channel, voltage gated modifier subfamily 
G, member 1
Potassium channel subunit
KCNG1 36 5 -7,6 0,0065
potassium voltage-gated channel, subfamily G, 
transcript variant X2
Potassium channel
ITGAX 4 57 15,1 0,0035
 integrin, alpha X (complement component 3 receptor 
4 subunit), transcript variant 2
Alpha chain of integrins. Binds fibrinogen
PPFIA4 9 99 11,5 0,0041
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), alpha 
4
May regulate the disassembly of focal adhesions
WISP2 4 38 9,5 0,0088  WNT1 inducible signaling pathway protein 2
inhibits the binding of fibrinogen to integrin 
receptors
CDH15 6 36 6,3 0,0123  cadherin 15, type 1, M-cadherin (myotubule) Calcium-dependent cell adhesion proteins
PIGZ 357 1594 4,5 0,0009
 phosphatidylinositol glycan anchor biosynthesis, class 
Z
Involved in GPI anchor biosynthesis
PCDHB5 18 4 -4,1 0,0092  protocadherin beta 5
Potential calcium-dependent cell-adhesion 
protein.
BMP2 6 95 15,2 0,0059  bone morphogenetic protein 2 
Plays a role in bone and cartilage development
MMP13 2 12 5,5 0,0014  matrix metallopeptidase 13 (collagenase 3) Degradation of extracellular matrix
SPP1 4 27 6,1 0,0025  secreted phosphoprotein 1, transcript variant 1
Binds to hydroxyapatite. Forms an integral part 
of the mineralized matrix
SPRR1A 13 52 4,1 0,0014  small proline-rich protein 1A Protein of the keratinocyte membrane
SPRR2A 3 27 10,6 0,0005  small proline-rich protein 2A Protein of the keratinocyte membrane
SPRR2D 6 27 4,3 0,0004  small proline-rich protein 2D Protein of the keratinocyte membrane
CABP7 6 148 26,6 0,0012  calcium binding protein 7
Negatively regulates Golgi-to-plasma membrane 
trafficking
FAM71A 12 3 -4,2 0,0064  family with sequence similarity 71, member A Important for integrity of the Golgi
UNC13D 299 68 -4,4 0,0040  unc-13 homolog D (C. elegans) Regulates assembly of recycling and late 
endosomal structures
PPP2R2C 2 26 11,1 0,0002
 protein phosphatase 2, regulatory subunit B, gamma, 
transcript variant 1
Negatively controls cell growth and division
LMO2 16 4 -4,0 0,0377
 LIM domain only 2 (rhombotin-like 1), transcript 
variant 1
Crucial role in hematopoietic development
CYR61 2166 184 -11,8 0,0021  cysteine-rich, angiogenic inducer, 61
Promotes cell proliferation, chemotaxis, 
angiogenesis and cell adhesion
ASB2 2 20 8,4 0,0038
 ankyrin repeat and SOCS box containing 2, transcript 
variant 2
Subunit of a E3 ubiquitin ligase complex that 
mediates the degradation of actin-binding 
proteins.
RNF183 110 580 5,3 0,0010  ring finger protein 183 E3 ubiquitin ligase
CDRT1 13 3 -4,3 0,0068
 CMT1A duplicated region transcript 1, transcript 
variant 1
Ubiquitin ligase
NDRG1 3283 31299 9,5 0,0002  N-myc downstream regulated 1, transcript variant 2
Involved in stress response. Necessary for p53-
dependent caspase activation and apoptosis
UNC5B 1139 244 -4,7 0,0023  unc-5 homolog B (C. elegans), transcript variant 1
Netrin receptor activating apoptosis in the 
absence of its ligand
WFDC2 47 210 4,5 0,0267  WAP four-disulfide core domain 2 Broad range protease inhibitor
Protease 
regulation















GDAP1L1 101 22 -4,7 0,0074
 ganglioside induced differentiation associated 
protein 1-like 1, transcript variant 2
Expressed after neuron differentiation induced 
by ganglioside GD3
SCGB2A1 6 27 4,6 0,0172  secretoglobin, family 2A, member 1 May bind androgens and other steroids
EDN1 216 26 -8,4 0,0029  endothelin 1, transcript variant 1 Vasoconstricting peptide
FAM167A 18 4 -4,7 0,0443  family with sequence similarity 167, member A 
ANKFN1 10 2 -4,6 0,0010
 ankyrin-repeat and fibronectin type III domain 
containing 1
KIAA0825 12 3 -4,3 0,0054 KIAA0825
TMEM45A 4 17 4,2 0,0131  transmembrane protein 45A
CLIP4 2 14 6,1 0,0054
 CAP-GLY domain containing linker protein family, 
member 4, transcript variant 1
C4orf47 31 203 6,5 0,0022  chromosome 4 open reading frame 47

























































































A search for genes differentially modulated by 3D culture depending on the 
expression or non-expression of B4GALNT2 yielded a list of 31 genes, 13 of which 
showed up-regulation in response to 3D culture only in S2/S11 cells, while the 
remaining 18 showed down-regulation in response to 3D culture only in S2/S11 cells 













































Table 7. Genes highly modulated by 3D only in B4GALNT2-expressing LS174T cells 
(clones S2/S11).  
 
 
Corrected p value was calculated using the multiple test correction Benjamini-Hochberg (p 
< 0.05, fold change B4GALNT2 3D vs B4GALNT2 2D). Information on the gene role was 
obtained from: https://www.genecards.org and from PubMed. 







KIZ 16,2 13,4 19,0 3,8 -1,2 -4,9 0,0086 kizuna centrosomal protein
Centrosomal protein necessary to endure the forces 
converging on the centrosomes during spindle formation.
CEP120 7,3 7,5 15,8 3,1 1,0 -5,2 0,0086 centrosomal protein 120kDa
Functions in the microtubule-dependent coupling of the 
nucleus and the centrosome.
DNAH6 6,3 5,3 13,1 2,3 -1,2 -5,7 0,0163
dynein, axonemal, heavy 
chain 6
Member of the dynein family, which are constituents of the 
microtubule-associated motor protein complex.
SGOL2 8,6 7,7 18,4 2,2 -1,1 -8,3 0,0086 shugoshin-like 2 (S. pombe)
Targets PPP2CA to centromeres, leading to cohesin 
dephosphorylation.
STARD13 13,5 16,3 19,8 4,2 1,2 -4,7 0,0156
StAR-related lipid transfer 
(START) domain containing 13
Involved in regulation of cytoskeletal reorganization, cell 
proliferation and motility.
UPK1A 4,0 3,7 1,9 12,0 -1,1 6,3 0,0086 uroplakin 1A
Member of the tetraspanin family, mediates signaling. 
Decreased expression is associated with CRC progression and 
poor prognosis. (PMID: 25197375)
OR52R1 11,2 10,3 3,3 15,5 -1,1 4,8 0,0131
olfactory receptor, family 52, 
subfamily R, member 1 
(gene/pseudogene)
Olfactory receptors are G-protein-coupled receptors involved 
in perception of smell and other functions. 
TAS2R45 42,6 35,9 68,8 17,2 -1,2 -4,0 0,0247
taste receptor, type 2, 
member 45
TAS2R19 41,9 31,8 70,3 17,1 -1,3 -4,1 0,0116
taste receptor, type 2, 
member 19
TAS2R30 254,5 215,3 402,3 81,8 -1,2 -4,9 0,0168
taste receptor, type 2, 
member 30
TNFAIP8L2 4,7 6,0 2,0 14,5 1,3 7,3 0,0319
tumor necrosis factor, alpha-
induced protein 8-like 2
Promotes Fas-induced apoptosis. (PMID: 28186089)
MYOD1 3,4 5,7 2,3 10,4 1,7 4,4 0,0239 myogenic differentiation 1 Mediates apoptosis through caspase 3. (PMID: 28131747)
PPM1K 16,3 11,7 25,7 4,0 -1,4 -6,5 0,0086
protein phosphatase, 
Mg2+/Mn2+ dependent, 1K
Regulates the mitochondrial permeability transition pore and 
is essential for cellular survival.
SDPR 
(CAVIN2)
4,3 1,8 18,3 2,3 -2,4 -8,1 0,0106 serum deprivation response
Role in caveolar biogenesis and morphology. Metastasis 
suppressor and activator of apoptosis. (PMID: 26739564).
PHF20L1 7,4 7,1 24,2 2,7 1,0 -8,9 0,0089 PHD finger protein 20-like 1
Predicted to be involved in regulation of transcription. 
Stabilizes SOX2 postranslationally. (PMID: 30089852)
KLF12 5,2 3,9 12,3 2,2 -1,3 -5,7 0,0235 Kruppel-like factor 12
Inhibitor of the AP-2 alpha transcription factor. Inhibits 
growth and anoikis resistance of ovarian cancer cells. (PMID: 
28095864)
PCF11 3,6 5,0 6,7 1,7 1,4 -4,0 0,0086
PCF11 cleavage and 
polyadenylation factor subunit
It is necessary for efficient Pol II transcription termination
CTLA4 2,1 3,7 2,4 14,2 1,7 5,8 0,0136
cytotoxic T-lymphocyte-
associated protein 4
Inhibitor of T cell activation.
IL1A 1,7 2,8 2,1 11,7 1,7 5,6 0,0259 interleukin 1, alpha Involved in immune responses and inflammatory processes. 
TDO2 3,1 6,5 7,3 29,0 2,1 4,0 0,0086 tryptophan 2,3-dioxygenase
In tryptophan metabolism catalyzes the first step of the 
kynurenine pathway. Increased kynurenine may suppress 
antitumor immune responses.
FSIP2 8,3 5,8 17,0 2,9 -1,4 -5,9 0,0365
fibrous sheath interacting 
protein 2
Protein associated with the sperm fibrous sheath.
SPACA1 5,5 6,4 4,1 18,2 1,2 4,5 0,0293 sperm acrosome associated 1
Localizes to the acrosomal membrane of spermatozoa, 
playing a role in acrosomal morphogenesis and in sperm-egg 
fusion.
USP11 6,1 7,0 3,3 13,3 1,1 4,0 0,0352 ubiquitin specific peptidase 11
Encodes a cysteine protease that cleaves ubiquitin from 
ubiquitin-conjugated protein substrates. 
Ubiquitinatio
n
ST13 6,9 12,8 2,7 11,0 1,9 4,1 0,0090
suppression of tumorigenicity 
13 (colon carcinoma) (Hsp70 
interacting protein)




HIST4H4 81,2 193,8 101,6 406,8 2,4 4,0 0,0365 histone cluster 4, H4 Component of the nucleosome.
Chromatin 
structure
TRAPPC2 10,3 7,1 8,4 1,9 -1,5 -4,4 0,0086
trafficking protein particle 
complex 2




C8orf74 6,3 5,3 10,1 2,3 -1,2 -4,4 0,0135
chromosome 8 open reading 
frame 74
NAALADL2 15,5 10,4 17,9 4,1 -1,5 -4,3 0,0196
N-acetylated alpha-linked 
acidic dipeptidase-like 2
SAMD12 21,1 17,1 25,8 6,3 -1,2 -4,1 0,0323
sterile alpha motif domain 
containing 12
FRG2 40,8 49,1 40,2 173,8 1,2 4,3 0,0138 FSHD region gene 2
FRG2C 3,5 8,4 7,2 35,0 2,4 4,9 0,0124








































Taste receptors play a role in the perception of bitterness and 
in sensing the chemical composition of the gastrointestinal 
content. Some taste receptors inhibit cancer growth and 
stemness. (PMID: 28467517)



















































Yet, data collected from microarray analysis of LS174T cells grown in anchorage-
independent conditions as spheroids were compared to gene expression data of 
TCGA cohorts (Non- and High- B4GALNT2 expressers). The rationale of the study 
is explained by the notion that 3D spheroids resemble the tumor in vivo with respect 
to its morphological features, microenvironment, volume growth kinetics, oxygen 










































Table 8. Gene expression comparison between TCGA cohort (Non- and High 
B4GALNT2 expressers and microarray analysis of LS174T cells (modulated by 3D 




The mean level of expression in TCGA database of genes selectively modulated by 3D 
growth only in S2/S11 cells (Table 7) was compared in the cohorts of non-B4GALNT2 
expressers and high B4GALNT2 expressers. The column “Consistency” indicates whether 
the difference observed in the cohorts was consistent with that reported in Table 7. Genes 
showing statistically significant consistent difference are indicated in bold (p ≤ 0.05 
Student’s t test for independent samples). N.S. = non-significant. A few genes present in 




CHAPTER V - RESULTS 
Transcriptomic and phenotypic impact of B4GALNT2 
expression in SW480 and SW620 CRC cells 
Note: Results presented in this section were taken from the published manuscript:  
- Pucci, Michela; Gomes Ferreira, Inês; Malagolini, Nadia; Ferracin, Manuela and 
Dall’Olio, Fabio “The Sda Synthase B4GALNT2 Reduces Malignancy and Stemness in 
Colon Cancer Cell Lines Independently of Sialyl Lewis X Inhibition” Int. J. Mol. Sci. 2020, 
21, 6558 
5.1 Transfection of SW480 and SW620 with FUT6 and 
B4GALNT2 cDNAs 
Stemming from TCGA transcriptomic data that indicate CRC patients with higher 
B4GALNT2 expression level display longer overall survival and the significant 
impact of B4GALNT2 expression on the phenotype of LS174T cells, the second part 
of the research aimed at understanding whether the effects were due to the expression 
of the Sda antigen or inhibition of sLex antigen or both. To this scope, the expression 
of FUT6 or B4GALNT2 was forced in the CRC cell lines SW480 and SW620. The 
two colon cancer cell lines were chosen essentially for two reasons. First, they both 
lacked FUT6 and B4GALNT2 enzyme activities and sLex and Sda antigens. Second, 
they were derived from the primary tumor (SW480) and a lymph node metastasis 
(SW620) of the same patient, allowing the investigation of the effect of the two 
enzymes at different tumor stages. In both SW480 and SW620 cell lines, transfection 
of B4GALNT2 cDNA induced the expression of Sda
  
antigen, whereas introduction 
of FUT6 plasmid led to sLex expression. The mRNA level of the two 
glycosyltransferases, as detected by microarray analysis, was negligible in mock 
transfectants but well expressed in the respective glycosyltransferase transfectants 
(Figure 22A). In FUT6 transfectants the level of FUT6 mRNA was very high, in 
B4GALNT2 transfectants the level of B4GALNT2 mRNA was lower, although 





Figure 22. Biochemical characterization of FUT6 or B4GALNT2-transfected cell lines. 
A:  Slot blot analysis of Neo cells and of FUT6- or B4GALNT2-transfected clones with anti 
sLex or anti Sda antibodies. B: mRNA expression determined by microarray analysis and 
expressed in arbitrary units of the two enzymes in Neo (mock transfectants) or populations 
transfected with FUT6 or B4GALNT2. 
 
 
5.2 Phenotypic changes induced by B4GALNT2 and FUT6 
expression  
To unravel the relative contribution of the Sda and sLex antigens to the phenotype of 
the two cell lines, the following aspects of cancer cells growth and malignancy were 
analyzed in vitro.  
 DOUBLING TIME ASSAY 
In order to evaluate the incidence of the two antigens on the cellular proliferation 
rate of the two lines, the doubling time (DT) was measured. The aim was to evaluate 
the time it takes for a population to double its size. In this assay, the cells were 
counted 24 hours apart three times. At the end of the measurements intervals it was 
found that expression of B4GALNT2 reduced the growth rate of SW620, increasing 
the doubling time from 23 ± 3 to 28 ± 4 h (Figure 23A ). Although a tendency to 
increased speed of growth in FUT6-expressing SW620 cells was observed, it did not 
reach statistical significance. On the other hand, no effect of either 
glycosyltransferase was observed on the doubling time of SW480. 
FUT6 mRNA expression 
 
B4GALNT2 mRNA expression 
SW480 SW620 Transfection SW480 SW620 
4 3 Mock 7 14 
11430 1390 FUT6 2 3 






 CLONOGENIC ASSAY  
 
To investigate whether the presence of either glycosyltransferase and their cognate 
antigens was able to affect the number of cells able to generate a colony in standard 
conditions of growth it was performed a colony formation assay. A small number of 
mock-transfected and FUT6- and B4GALNT2- SW480 and SW620 transfected cells 
were seeded in standard conditions in a way that they could grow independently. 
After the incubation time, the number of cells able to form colonies resulted to be 
affected by both glycosyltransferases in both cell lines (Figure 23 B). The cell line 
SW620 was provided with a higher capability to form colonies, compared to SW480. 
However, in both cell lines FUT6 expression induced a small but significant increase 
of the clonogenic ability which, by contrast, was strongly impaired by B4GALNT2.  
 
 ANCORAGE INDEPENDENT GROWTH IN SOFT AGAR 
 
SW480 and SW620 cells were analyzed for their ability to grow without anchorage 
to a solid surface by a soft agar assay. In this study, the cells were plated as a single 
cell within a layer of agar to mimic the growth in absence of adhesion. After the 
incubation time, SW480- and SW620- FUT6 and B4GALNT2 transfected cells were 
compared with mock-transfected Neo cells for their ability to form colonies. In both 
cell lines, B4GALNT2 expression significantly reduced the formation of clones, 
while FUT6 induced a slight increase of clone formation only in SW620 cells (Figure 
23 C).  
 
 3D TUMOR SPHEROIDS  
 
SW480 and SW620 cells transfected either with FUT6 or B4GALNT2 and mock-
transfected were evaluated for their capacity to survive and grow in a liquid medium 
through a 3D tumor spheroids assay. This assay measures the ability of the cells to 
survive and proliferate without any mechanical anchorage, a condition associated 
with stemness, even more drastic than soft agar growth. SW480 cells formed mainly 
rounded spheroids with regular edges, whereas SW620 cells formed spheroids with 
irregular shape and many cells were found as single. B4GALNT2 expression 
reduced the formation of spheroids in both cell lines while FUT6 had no effect 
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(Figure 23 D), as resulted from protein quantification described in “Materials and 
methods” section. 
 
 WOUND HEALING ASSAY 
 
To evaluate whether the B4GALNT2 and FUT6 expression could modify the ability 
of cells to proliferate and migrate (an important feature associated with malignant 
transformation), wound healing assay was performed with SW480- , SW620- FUT6 
and -B4GALNT2 cells and  mock-transfected Neo cells. The ability to heal a wound 
in a layer of confluent cells provided an example of the differential response of the 
two cell lines to glycosyltransferase expression. In fact, in the cell line SW480 the 
expression of either FUT6 or B4GALNT2 left unaltered the ability to heal a wound. 
On the contrary, in the cell line SW620 the healing capability was greatly enhanced 
by FUT6 but reduced by B4GALNT2 (Figure 23 E).  
 
 ALDEFLUOR ASSAY 
 
To investigate whether the expression of the two glycosyltransferases and their 
cognate carbohydrate antigens could affect the stemness property of SW480 and 
SW620 lines, mock-transfected and FUT6- and B4GALNT2- expressing cells were 
analyzed for the expression of aldehyde dehydrogenase (ALDH).This assay for 
stemness revealed that B4GALNT2 induced a marked down-regulation of the 
number of stem cells in both cell lines (Figure 23 F). Unexpectedly, FUT6 induced 
a slight reduction of  ALDH positive cells, which reached statistical significance 











Figure 23. Phenotypic effects induced by FUT6 or B4GALNT2 expression. (A) 
Doubling time (DT),expressed in hours. (B) Colony formation assay in standard conditions 
of growth. Histograms indicate the total number of colonies. (C) Growth in 0.33% soft agar. 
Photographs were taken without magnification and the colonies visible to the naked-eye 
were counted. (D) Spheroids formation assay. The aspect of the spheroids is shown. The 
total amount of protein was calculated and taken as a measure of the cells grown in 3D 
conditions. (E) Wound healing assay. The free area of the wound was quantitated by ImageJ 
and normalized to the free area of the same cell line at 0 h, which was taken as 100%. The 
photographs show only the start (0 h) and the end point (96 h) of the healing process. Graphs 
in the bottom report the quantification of the healing process at each time point. The 
microphotographs were taken at a 4x magnification. (F)  ALDEFLUOR assay. Cells were 
incubated with ALDEFLUOR either in the presence or in the absence of the inhibitor N,N-
diethylaminobenzaldehyde (DEAB). Gates excluding all of the cells labelled in the presence 
of DEAB were set. Cells included in the gate in the absence of DEAB, were considered to 
be ALDH positive. Histograms report the percentage of ALDH positive cells ±SD in five 
independent experiments. Statistical analysis was performed using one-way analysis of 
variance (ANOVA) and Dunnett’s multiple comparisons test. ns,not significant; * p ≤ 0.05;  
** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001. 
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5.3 Impact of B4GALNT2 expression on the transcriptome 
of SW480 and SW620 colon cancer cells 
 
To establish whether and how the overexpression of FUT6 and B4GALNT2 could 
modify the gene expression profile of colorectal cancer cells, two independent RNA 
preparations of the six cell lines (SW480 and SW620 transfected with FUT6 or 
B4GALNT2 or mock-transfected) were microarray-analyzed. 
Genes significantly and consistently modulated either by FUT6 or B4GALNT2 in 
both SW480 and SW620 cells were identified. The impact on the transcriptome of 
the two glycosyltransferases was assessed by Pathway Enrichment analysis and 
found to be very different. In fact, FUT6 modulated 1779 genes while B4GALNT2 
modulated only 128 genes. Figure 24 is  a heat-map of the genes modulated by FUT6 
or B4GALNT2, compared with Neo in both SW480 and SW620 cell lines. 
Analysis showed a very different predicted impact on cell behavior (Table 8 A and 





Figure 24. Heatmaps of genes modulated upon FUT6 and B4GALNT2 expression. A: 
Cluster analysis of SW480 and SW620 cells transfected with FUT6 and compared with 
control Neo. B: Cluster analysis of SW480 and SW620 cells transfected with B4GALNT2 
and compared with control Neo. Differentially expressed genes are reported. Genes 
(columns) and samples (rows) were grouped by hierarchical clustering (Manhattan 
correlation). High- and low-expression was normalized to the average expression across all 
samples. Differences were analyzed by the moderated t-test. Corrected p-value cut-off: 0.05; 





In Table 9A and 9B are shown the ten most relevant networks modulated by FUT6 
and B4GALNT2 expression.  
 




Ten most relevant networks altered by FUT6 expression. Pathway map visualization was 
performed using MetaCore pathway analysis by GeneGo. 
 
 
Networks Network Objects 
Cell cycle_Mitosis
Cyclin B1, Cyclin B, Cyclin B2, Histone H3, PBK, Cyclin A, PLK1, Securin, CENP-H, SIL, 
Separase, HZwint-1, CENP-F, CAP-G/G2, Aurora-A, CDC25, CDC25C, Tubulin beta, 
KNSL1, CAP-E, AF15q14, HEC, CENP-E, TPX2, SPBC25, ASPM, MAD2a, Survivin, BUB1, 
CAP-C, Actin, Histone H1, CENP-A
Cell cycle_Core
CDC45L, Cyclin B1, Cyclin B, Cyclin B2, Cyclin A, PLK1, Securin, RPA3, CENP-H, Separase, 
CAP-G, Aurora-A, CDC25C, CAP-E, p18, HEC, p21, CENP-E, ORC6L, CKS2, MAD2a, 
Survivin, BUB1, CAP-C, CENP-A
Cytoskeleton_Spindle microtubules
Cyclin B1, Cyclin B, Cyclin B2, KIF4A, DEEPEST, PLK1, Securin, CENP-H, GTSE1, Separase, 
HZwint-1, CENP-F, Aurora-A, Tubulin beta, KNSL1, Tau (MAPT), HEC, MKLP2, CENP-E, 
CKS2, MAD2a, BUB1, CENP-A
Development_Regulation of 
angiogenesis
MMP-9, FOXM1, IL-8, PKC, CD13, Oct-3/4, TRIP6, TrkB, GLI-1, WT1, DBH, Cathepsin B, 
Ephrin-B, Ephrin-A, PLC-beta, Galpha(i)-specific peptide GPCRs, c-Myc, IL8RB, 
Galpha(q)-specific peptide GPCRs, PI3K reg class IA, STAT5, IL-15, Ephrin-A receptors, 
p21, Plasminogen, Angiostatin, Plasmin, Ephrin-B receptor 4, Ephrin-B receptors, IP3 
receptor, IL-1RI, Ihh, Hedgehog, EGFR, PLAUR (uPAR), EDNRB
Cell cycle_G2-M
FOXM1, Cyclin B1, Cyclin B, Cyclin B2, Histone H3, MYRL2, MRLC, Cyclin A, Cyclin A2, 
PLK1, Securin, GTSE1, Claspin, CAP-G, CAP-G/G2, Aurora-A, CDC25, CDC25C, RGC32, 
KNSL1, CAP-E, c-Myc, p21, Rad51, BLM, CKS2, MAD2a, BUB1, EGFR, CAP-C, Histone
H1.5, Histone H1, FANCD2
Cell cycle_S phase
CDC45L, Cyclin B1, Cyclin B, Cyclin B2, Histone H3, Cyclin A, Cyclin A2, Histone H4, 
PLK1, Securin, RPA3, Separase, DRF1, PDS5, RGC32, PRIM2A, p21, ORC6L, Rad51, AHR, 
DDX11, BUB1, Histone H1.5, Histone H1, Sgo1
Cell cycle_Meiosis
Cyclin B1, HSP70, Cyclin A, GCNF, PARD3, PLK1, Securin, SMC1L2, FANCG, RAD54L, 




FGF7, APOE, Syntaxin 1A, TrkB, ErbB3, nAChR alpha, WNT, Ephrin-B3, Ephrin-B, 
Neurexin beta, Ionotropic glutamate receptor, Kainate receptor, NT-4/5, Neuregulin 2, 
NMDA receptor, Frizzled, MAGI-1(BAIAP1), FGFR2, Synaptotagmin VII, Synaptotagmin, 
Ephrin-B receptors, X11, FGFR4, Endophilin A3, Actin, NR1
Cell adhesion_Attractive and 
repulsive receptors
5T4, Semaphorin 3A, MENA, SLIT1, c-Fes, UNC5B, AF-6, Ephrin-B3, Ephrin-B, Ephrin-A, 
Ephrin-A3, Ephexin, Tau (MAPT), L1CAM, PI3K reg class IA (p55-gamma), PI3K reg class
IA, Ephrin-A receptors, Ephrin-A receptor 3, Collagen XIII, Ephrin-B receptor 4, Ephrin-B 
receptors, RHO6, Actin, Integrin, Intersectin
Development_Neurogenesis_Axonal
guidance
AHNAK, Syntenin 2, APOE, Semaphorin 3A, PKA-reg (cAMP-dependent), PARD3, 
CRMP4, TrkB, MENA, SLIT1, c-Fes, Ryanodine receptor 1, UNC5B, Ephrin-B3, Ephrin-B, 
Ephrin-A, Ephrin-A3, PLC-beta, NT-4/5, L1CAM, PI3K reg class IA, Ephrin-A receptors, 
Ephrin-A receptor 3, Guanine deaminase, Ephrin-B receptor 4, Ephrin-B receptors, 
RHO6, IP3 receptor, Actin, Integrin





Ten most relevant networks altered by B4GALNT2  expression. Pathway map visualization 
was performed using MetaCore pathway analysis by GeneGo. 
 
To obtain more detailed information on the possible phenotypic effects of the 
expression of the two glycosyltransferases, the analysis  was restricted to the genes 
showing a level of expression either in Neo or in glycosyltransferase-transfected 
cells ≥ 50 and a fold change ≥ 3 for FUT6 (owing to the much greater number of 
modulated genes) (Table 10) or ≥ 2 for B4GALNT2 (Table 11). The main role of 
each gene was deduced from the GeneCards web site (https://www.genecards.org/). 
Out of the 63 FUT6-modulated genes reported in Table 10, 10 displayed up-
regulation, whereas 53 were down-regulated. Among the 45 genes included in Table 
11, 11 showed up-regulation while 34 displayed down-regulation in B4GALNT2 
expressing SW480 and SW620 cells. 
B: B4GALNT2 modulated 
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subfamily J, member 2 







Involved in processing step during 
piRNA biosynthesis. 
CPLX2 
19.3 68.9 complexin 2 
Positively regulates a late step in 






Binds to various kinds of negatively 
charged substances such as heparin, 
phospholipids, and dextran sulfate 
SNORA30 
90.3 284.3 
small nucleolar RNA, 
H/ACA box 30 
Small nucelolar RNA 
OXR1 
143.2 446.1 oxidation resistance 1 




myosin, heavy chain 7B, 
cardiac muscle, beta 
Involved in muscle contraction 
CENPI 
27.3 84.3 centromere protein I 
Involved in accurate chromosome 
alignment and segregation 
CAPN15 254.5 767.0 calpain 15 May function as a transcription factor 
SNORA62 
272.5 815.1 
small nucleolar RNA, 
H/ACA box 62 
Small nucelolar RNA 
CD55 
338.7 114.6 
CD55 molecule, decay 
accelerating factor for 
complement (Cromer 
blood group) 




containing ion transport 
regulator 4 






Plays a role in the regulation of the 
mitotic cell cycle progress and the 
onset of mitosis. Regulates 






Little or no information 
CFAP70 
161.0 52.2 
cilia and flagella 
associated protein 70 
Little or no information 
 
XDH 156.0 50.5 xanthine dehydrogenase Key enzyme in purine degradation 
MCAM 
1107.7 355.3 
melanoma cell adhesion 
molecule 








chromosome 11 open 
reading frame 96 







Subunit of the NADPH oxidase 
complex found in neutrophils, which 
produces superoxide to kill bacteria 
RASGEF1A 
128.6 40.7 
RasGEF domain family, 
member 1A 
Guanine nucleotide exchange factor 
specific for RAS 
FAM228B 
347.8 109.9 
family with sequence 
similarity 228, member B 
Little or no information 
CAPN5 
1312.9 413.2 calpain 5 
Calcium-dependent cysteine protease 
involved in signal transduction 
SLIT1 
60.3 18.8 
slit homolog 1 
(Drosophila) 




brain expressed X-linked 
2 
Regulator of mitochondrial apoptosis 
and G1 cell cycle. Regulates 
transcription. Tumor suppressor. 
WDR78 53.2 16.5 WD repeat domain 78 Little or no information 
CAPN8 
72.3 22.2 calpain 8 
Involved in membrane trafficking in 
mucus cells 
SCEL 
1132.9 343.4 sciellin 
May function in the assembly or 






receptor type 13 (APO-
1/CD95 (Fas)-associated 
phosphatase) 
Tyrosine phosphatase which 
regulates negatively FAS-induced 
apoptosis 
TPSAB1 
63.6 18.8 tryptase alpha/beta 1 





family, member e41 
Transcriptional repressor involved in 
the regulation of the circadian rhythm 
FILIP1 
58.2 16.9 
filamin A interacting 
protein 1 
By acting through a filamin-A/F-actin 
axis, it controls the start of 
neocortical cell migration 
REPS2 
59.3 17.0 
RALBP1 associated Eps 
domain containing 2 




bound protein 10 
Binds to insulin and insulin like 




guanylate binding protein 
3 
Encodes a member of the guanylate-










Promotes apoptosis by interacting 





protein 2 homolog C 
(Drosophila) 




inhibitor, clade E (nexin, 
plasminogen activator 
inhibitor type 1), member 
2 




234.5 59.5 complexin 1 
Positively regulates a late step in 








Serine protease inhibitor that 
regulates the tissue factor (TF)-




adrenergic, beta, receptor 
kinase 2 
Phosphorylates the agonist-occupied 
form of the β-adrenergic receptor 








endothelial PAS domain 
protein 1 
Transcription factor involved in the 




aggregation receptor 1 
Platelet receptor that signals upon the 




element binding protein 5 
Binds to the cAMP response element 
and activates transcription 
AHNAK2 
98.3 22.9 AHNAK nucleoprotein 2 
May play a role in calcium signaling 
by associating with calcium channel 
proteins 
ZNF462 
125.8 28.7 zinc finger protein 462 




chromosome 16 open 
reading frame 45 
Little or no information 
AKAP12 
1432.1 303.7 
A kinase (PRKA) anchor 
protein 12 
Associates with protein kinases and 
phosphatase, serving as a scaffold 
protein in signal transduction 
PRDM13 177.8 36.3 PR domain containing 13 Little or no information 
BEST1 
177.2 34.8 bestrophin 1 
Forms calcium-sensitive chloride 
channels 





G-protein coupled receptor which is 
activated by type IV collagen 
ANTXR2 
175.4 32.6 anthrax toxin receptor 2 
Necessary for cellular interactions 









1559.3 247.2 tubulin, beta 2B class IIb 





potential cation channel, 
subfamily V, member 6 
Mediates Ca(2+) uptake in various 
tissues, including the intestine 
HES7 
84.9 10.4 
hes family bHLH 







Involved in heparan sulfate 
biosynthesis 





Calcitonin and related receptors are a 




“Mean Neo” and “Mean FUT6” represent the mean expression value of SW480 and SW620 
Neo- and FUT6-expressing cells respectively. Are reported only protein coding genes 
showing a fold change “Mean FUT6 / Mean Neo” ≥3, a corrected p value ≤ 0.05 and a level 




































Table 11.  Genes up- or down-regulated in both SW480 and SW620 cells in response 











G0S  785 1603 G0/G1 switch 2 Promotes apoptosis by 







   
468 898 Origin recognition 
complex, subunit 6 
Coordinates chromosome 






7025 12027 Cell division cycle 
associated 5 
Regulator of sister 







268 457 Minichromosome 
maintenance complex 
component 10 
Acts as a DNA replication 
initiation factor. Prevents 











Can be a transcriptional 
activator or repressor. 
Behaves as an oncogene or  






3920 6365 Peptidylprolyl 
isomerase H 
(cyclophilin H) 











354 575 Ankyrin repeat 
domain 32 
 
Involved in the DNA damage 







1721 2788 Solute carrier  















1835 2889 Metastasis  
associated 1 family, 
member 2 
Involved in transcription 
regulation as repressor and 







138 90 Zinc finger  
protein 276 







1881 1228 Discoidin domain 
receptor tyrosine 
kinase 1 
Receptor tyrosine kinase 
acting as a cell surface 
adhesion molecule, 














373 236 Iduronate 2-sulfatase 
 
Lysosomal enzyme involved 
in the degradation of 






1942 1243 Spire-type actin 
nucleation factor 2 
Actin nucleation factor 
involved in intracellular 
vesicle transport and for 







358 232 Nucleoredoxin 
 
Functions as a redox-
dependent negative 
regulator of Wnt signaling 







4889 2894 Melanoma antigen 





1245 740 Lectin, galactoside-











9495 5535 Spondin 2, 
extracellular matrix 
protein 
Functions as an opsonin for 






80 47 Zinc finger protein 83 
 







66 38 Ring finger  
protein 157 
Ubiquitin ligase preventing 
apoptosis. Acts as a 
downstream effector of the 





81 45 Filamin A interacting 
protein 1-like 
When overexpressed in 
endothelial cells, leads to 
inhibition of cell 
proliferation and migration 






138 78 SRSF protein kinase 3 Phosphorylates the SR 
splicing factor SRSF1 
ABCC3 
  




May act as an inducible 
transporter in the biliary and 










epidermal growth factor 




4125 2379 Protein tyrosine 
phosphatase, 
receptor type, N 
polypeptide 2 
Regulates PI(4,5)P2 level in 
the plasma membrane and 
actin dynamics related to 
cell migration and 
metastasis 
BAIAP3 191 103 BAI1-associated 
protein 3 
Functions in endosome to 
Golgi retrograde transport. 
SLC4A11
  
1517 740 Solute carrier family 




cotransporter that is 







8740 4612 Sema domain, 
immunoglobulin 




Inhibits axonal extension 
and acts as a tumor 







6276 3199 Tubulin, beta 2A  
class IIa 
 
Component of microtubules, 
key participants in processes 






721 360 Aldo-keto reductase 
family 1, member C1 
 
In the liver and intestine, it 
may have a role in the 





299 142 Collagen, type VII, 
alpha 1 
 
May contribute to epithelial 
basement membrane 





1037 497 Synaptotagmin XIII 
 
May be involved in transport 






220 89 Keratin associated 
protein 3-2 
Member of the keratin-












250 99 Spectrin, beta,  
non-erythrocytic 5 
Binds actin and kinesin 
EMP1 
  
16043 6672 Epithelial membrane 
protein 1 





842 328 Regulator of cell cycle Overexpression activates or 





322 132 Cadherin-related 
family member 2 
Involved in cell-cell adhesion 
and contact inhibition in 




536 227 Phospholipase C, beta 
1 (phosphoinositide-
specific) 
Produces the second 
messenger molecules 

















119 35 Disrupted in 
schizophrenia 1 
Positively regulates Wnt-
mediated proliferation. Plays 






52 15 Cell death-inducing 
p53 target 1 






475 108 CD44 molecule 
(Indian blood group) 
Receptor for hyaluronic acid 
and other ligands 
 
“Mean Neo” and “Mean B4GALNT2” represent the mean expression value of SW480 and 
SW620 Neo- and B4GALNT2-expressing cells respectively. Are reported only protein 
coding genes showing a fold change “Mean B4GALNT2 / Mean Neo” ≥2, a p value ≤ 0.05 
and a level of expression either in Neo or in B4GALNT2 ≥ 50. 
 
 
A deeper analysis of gene expression data from SW480 and SW620 cells revealed 
that several genes appeared modulated by FUT6 expression in either SW480 or 
SW620 cells or both. To simplify the analysis, genes were divided by functional 




Table 12. Genes modulated by FUT6 expression in either SW480 or SW620 cells or 
both. 
 
Functional class Both in SW480 and 
SW620 
Only in SW480 Only in SW620 
Apoptosis BEX2; PTPN13; HRK  RSL1D1; BIRC3; PPM1K 
Ca binding CALB2  CAB39L 
Cell adhesion MCAM; GPR126; 
ANTXR2; SLIT1; PEAR1; 
NTN4 
ITGB7; NEBL CDH16; DOCK4; AGR2 

















TRIM58; FRMD4A; ANLN; 






  RAD51AP1 
Drug metabolism  CYB5R2 CYB5R2; CYP2J2; 
ADH1C 
Energy production  DNAJC15 DNAJC15 
Extracellular 
matrix 
SCEL; HS3ST1 COL9A3; COL6A1 FMOD; SDC4 
Glycosylation   GALNT18 
Growth factors MIA IGFBP2; MDK IHH; KITLG; WLS 
Growth factors 
receptors 
GRB10; GPR126; FZD6; 
CALCA 
NTRK2 GFRA3; EFNB3; GPR160; 
NOTCH2; RAMP1; SMO 
Hypoxia response HEPAS1 HIF1A  
Inflammation and 
immunity 
CD55; CXCL8; NCF2 ANXA1 RARRES2 
Intracellular 
transport 
CPLX2; CPLX1; CAPN8 MVB12B; SEZ6L2; 
GOLGA8A 
RAB36; HIP1; MVB12B; 
BLOC1S4; HTT; CPE; 
AGR2; SPIRE2 
Ion transport KCNJ2; AHNAK2; 
TRPV6; BEST1; FXYD4 
 TMC4; AKAP7; PIEZO1; 
MFSD10; BSPRY; MTL5; 
CACNA2D4; ATP6V0A4 
Lipid metabolism  LIPC; CYB5R2 PLIN4; LIPC;  CYB5R2; 
CYP2J2 
Mucosa protection  TFF1; TFF3; SLPI AGR2 
Nuclear structure 
and function 
 NPIPB5 NOP14 
Phosphatases  SGPP2 DUSP23; PPM1K 
Proteolysis SERPINE2; TIMP3; 
TPSAB1; TFPI 
 MME; WFDC2 









Only genes showing a fold change “Mean FUT6 / Mean Neo” ≥3, a p value ≤ 0.05 and a level of 
expression either in Neo or in B4GALNT2 ≥ 50 are reported. Genes up-regulated or down-regulated 




As FUT6 expression, B4GALNT2 expression modulated the gene expression in 
either SW480 or SW620 cells or both. To simplify the analysis, genes were divided 





































CHN2; SHCBP1; GPER1; 




PKIB; TSPAN5; RRAGD; 
PTPN13; GRB10; AKT3 
Stress response OXR1   
Transcription CAPN15; BEX2; 
BHLHE41; DIP2C; 
HEPAS1; CREB5; 
ZNF462; HES7; ZIC5 




PRRX1; KLF17; NELFA; 
ZNF581; MXD4; RCOR2; 
MXI1; ESSRA; MYCL; 
RELB; FOXD1; BCL3; 
ZNF22 
Translation  EEF1A2  











Table 13. B4GALNT2-modulated genes in either SW480 or SW620 or in both, 
grouped for functional classes.  
 
 
Functional class Both in SW480 and 
SW620 
Only in SW480 Only in SW620 
Apoptosis G0S2; CDIP1; LGALS7; 
RNF157; FILIP1L; 
SEMA3B 
RNF130 EVA1A; PTPN13; CDH13 
Cell adhesion CD44; CDHR2; DDR1 ELSPBP1; PCDH9 NEBL; SERPINB8 
Cell cycle ORC6; DISC1; RGCC  CDK14; BRSK2 
Chromatin 
remodelling 
MTA2 ING4; BAZ2B ATRX; ZNF462 
Cytoskeleton-
cytokinesis 
ORC6; CDCA5; MCM10; 
DISC1; SPIRE2; PTPRN2; 
SEMA3B; TUBB2A; 
KRT15; SPTBN5 
DLC1; SHROOM2 CENPI; ASPM; ERCC6L; 
NUF2; ANLN; CEP152; 
KIFC3; MAP1LC3B; 






 RAD51AP1; ERCC6L; 
DNA2; ARHGAP11A 





COL7A1; KRTAP3-2 ECM2; COL9A3  
Glycosylation  GALNT18; GALC; 
AMY1C 
FUT3 
Growth factors  IGFBP2; ANGPTL2; 




RHBDF1 NOTCH2; ROR1; 
EFNA1 
 












LPHN2; KIFC3; RAB37; 
GOLGA7B 











IDS   
Mucosa protection   MUC6 
Phosphatases PTPRN2 SGPP2 PTPN13 
Proteolysis  TPP2 ADAM30; SERPINA3 















RAB37; ADRB2;  TBC1D4 
Stress response  HSPA1A  
Transcription MAF; MTA2; ZNF276; 






; A2; ZNF276; 




















Only genes showing a fold change “Mean B4GALNT2 / Mean Neo” ≥2, a p value ≤ 0.05 
and a level of expression either in Neo or in B4GALNT2 ≥ 50 are reported. Genes up-
regulated or down-regulated are marked in red or blue, respectively. 
 
 
Surprisingly, it was found that transfection with either glycosyltransferase cDNA 
induced consistent gene modulation in one of the two cell lines. For example, the 
gene ANLN, which encodes for an actin-binding protein required for cytokinesis, 
was up-regulated in SW620 by expression of either B4GALNT2 or FUT6. In Table 
14 are shown the ten genes consistently modulated by expression of either FUT6 or 
B4GALNT2 classified in functional classes.  
The genes ANLN and RAD51AP1 are up-regulated in SW620 by expression of either 
glycosyltransferase. The genes CYB5R2, IGFBP2, SGPP2, LEF1 are up-regulated 
in SW480 by expression of either FUT6 or B4GALNT2 while COL9A3, PLCB1, 























Table 14. Genes consistently modulated by expression of either FUT6 or B4GALNT2, 
grouped for functional classes. 
 















CYB5R2 Involved in desaturation and 
elongation of fatty acids, 
cholesterol biosynthesis, drug 
metabolism 
Drug metabolism SW480 Up 





IGFBP2 Binds to IGF, prolonging its 
activity 
Growth factors SW480 Up 
SGPP2 Degrades the bioactive 
signaling molecule sphingosine 
1-phosphate 
Phosphatases SW480 Up 
PLCB1 Production of the second 
messenger molecules 






LEF1 Transcription factor of the Wnt 
signaling, activates MYC and 
CCND1 expression and 
enhances proliferation of 
pancreatic tumor cells 
Transcription SW480 Up 
ABCC3 May act as an inducible 
transporter in the biliary and 
intestinal excretion of organic 
anions 
Transporters SW480 Down 








The study of B4GALNT2 expression in SW480 and SW620 cells revealed a 
remarkable cell specificity of the glycosyltransferase. Thus, the further investigation 
evaluated the effects of B4GALNT2 expression in SW480 and SW620 with those 
previously observed in the B4GALNT2-transfected cell line LS174T in search of a 
“B4GALNT2 signature”, common to the three cell lines.  
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In Table 15, it is presented a signature of seven protein coding genes as a results of 
the statistical analysis performed to search a B4GALNT2 signature common to three 
cell lines employed for the study. It was attributed a function in cancer by an 
































Table 15. Genes consistently modulated by B4GALNT2 expression in SW480, SW620 
and LS174T. 
 Expression level  
LS174T SW480 SW620 
Gene 
symbol 










PLLP 104 52 674 441 803 509 Plasmolipin Little or no 
information 
 



















Little or no 
information 
 









COL20A1 14 8 40 21 54 28 Collagen 


















“Neo” and “B4GALNT2” refer to the mean expression value of the gene in the six cell 
populations. The seven genes are the only showing a statistically significant (p≤0.05) 
different expression level in B4GALNT2, compared with Neo in the three cell lines.  
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Unlike many other diseases, CRC is preventable and potentially curable when 
diagnosed in its early stages. However, it may remain often undetected due to the 
unspecific symptoms11. Current screening techniques are invasive or lack either 
sensitivity or specificity. A key point in the management of CRC is the identification 
of patients at higher or lower risk of recurrence and progression, to spare the most 
aggressive (and sometimes expensive) therapies to lower risk patients. To this aim, 
it is really essential to identify biological markers useful for patients’ stratification. 
Glyco-markers are particularly suitable for this purpose. During colorectal cancer 
oncogenesis, many glyco-antigens undergo remarkable changes and can  contribute 
significantly to cancer development and progression. Amongst the carbohydrate 
structures, the Sda antigen, synthesized by the glycosyltransferase B4GALNT277, is 
down-regulated in colorectal cancer.  
The clinical implications of its dramatic down-regulation in CRC are investigated 
for the first time in this work. This was pursued through the analysis of TCGA data 
to search a correlation between gene expression and clinical parameters. First of all, 
TCGA data confirm in a large cohort of samples that mRNA of B4GALNT2 is 
dramatically decreased in CRC, compared to normal tissue, consistent with a 
reduced B4GALNT2 enzymatic activity in CRC tissues previously reported by the 
group. The finding that patients expressing the highest levels of B4GALNT2 mRNA 
in their cancer tissues display longer survival and better response to therapy provides 
the first clinical demonstration of the relationship between high B4GALNT2 
expression and lower malignancy. This was consistent with the observed association 
of high B4GALNT2 with non-mucinous phenotype and wild type TP53 status.  On 
the other hand, no relationship was observed with clinical stage and microsatellite 
instability status. Interestingly, B4GALNT2 mRNA expression exhibits a prognostic 
predictive potential in CRC exceeding that of all the glycosyltransferases tested in 
this work and is even better than that of many oncogenes and tumor-suppressor 
genes. Among those tested, only SMAD6, encoding an inhibitor of TGF-β signaling, 
and TERT, that encodes the reverse transcriptase subunit of telomerase, displayed a 
better prognostic value than B4GALNT2, which equals that of EGFR. A possible 
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explanation for the lack of relationship with patients’ overall survival is provided by 
the fact that oncogene activation or tumor-suppressor inactivation can be due to 
mutations, altered phosphorylation, mislocalization, rather than increased or 
decreased mRNA expression. Patient stratification according to B4GALNT2 mRNA 
expression revealed that high B4GALNT2 expressers displayed a concomitant high 
level of other genes associated with positive prognosis, such as ZG16, ITLN1, BEST2 
and GUCA2B. These data support the notion that B4GALNT2 is a key member of a 
gene signature associated with good prognosis. 
Patients expressing the highest and lowest levels of B4GALNT2 display also 
glycosylation genes differentially modulated. Differential expression of several 
glycosyltransferases predicts that cancer cells of high B4GALNT2 expressers 
display higher levels of mucin-type O-glycosylation (GALNT8) with sugar chains 
terminating with sialyl-Tn, (ST6GALNAC1), sialyl-6-T structures (ST6GALNAC2) 
and Core 3 structures (B3GNT6); increased biosynthesis of type 1 chains (B3GALT5) 
and increased α2,3 sialylation of type 2 chains (ST3GAL4), forming acceptor 
substrates for B4GALNT2. ST6GAL1 and ST6GAL2 showed reduced expression, 
suggesting that α2,6-sialylation could be reduced in HBE. Among non-
glycosyltransferase molecules, it is worth mentioning the higher expression of 
galectin 4, which is associated to normal gut, and of the gel-forming mucins MUC2, 
MUC4 and MUC5B in HBE. These data suggest that in LBE and HBE cohorts 
different glycophenotypes exist.  
Data collected in silico indicate complex mechanisms controlling B4GALNT2 
expression in colonic tissues. The promoter region of the B4GALNT2 gene contains 
CpG islands suggesting that methylation can play a relevant role in B4GALNT2 
down-regulation in colon carcinogenesis. However, the general down-regulation of 
the gene observed in the vast majority of cancer cases cannot be explained by a 
differential methylation of the CpG sites located in the island and shores. Rather, the 
intronic open-sea site located between exon 6 and 7 presents a generally reduced 
methylation in cancer samples. Interestingly, methylation of this site is associated 
with increased, rather than decreased, B4GALNT2 expression. Thus, in some cases 
high methylation of specific sequences can have stimulatory effects due to the fact 
that it promotes interaction of distant enhancers with the regulatory regions of the 
gene133. However, in many samples B4GALNT2 was not expressed despite a 
permissive methylation status, indicating that other regulatory mechanisms are 
implicated. The glycosyltransferase expression might also be regulated by small non 
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coding RNAs (miRNAs). Several miRNAs are theoretically predicted to inhibit 
B4GALNT2 but miR-204-5p appears to be the most plausible candidate. In fact, it 
is the only one down-regulated in HBE and no one of the samples expressing 
B4GALNT2 above a background threshold expressed this miRNA. However, down-
regulation of this miRNA does not ensure B4GALNT2 expression, since many cases 
lacking miR-204-5p failed to express B4GALNT2. Thus, B4GALNT2 regulation 
appears to be multifactorial, with DNA methylation and miRNA expression playing 
a relevant but not exclusive role. The lack of appropriate transcription factors could 
be a plausible reason for the lack of B4GALNT2 expression in the majority of CRC 
samples.     
 
To understand whether high B4GALNT2 and lower malignancy were causally 
related, the impact of the forced expression of B4GALNT2 on the phenotype and 
the transcriptome of CRC in vitro was studied on three CRC cell lines transfected 
with B4GALNT2 cDNA. In the cell line LS174T, which constitutively expresses 
sLex, B4GALNT2 induced both sLex inhibition and Sda expression. Thus, the 
phenotypic and transcriptomic changes observed could not be separately attributed 
to the two antigens. To investigate separately the effects of Sda and sLex, the CRC 
cell lines SW480 and SW620, lacking the two antigens, were transfected with 
B4GALNT2 or FUT6.  
On LS174T cells, B4GALNT2 expression reduced some features associated with 
malignancy, such as soft agar growth, spheroid formation and ALDH expression, 
which are all associated with stemness. On the other hand, the proliferation rate, the 
clonogenic ability on solid substrates and the wound healing ability were not affected 
by B4GALNT2 expression in this cell line. 
It is commonly stated that sLex is the key player of malignancy while to B4GALNT2 
and Sda only an ancillary role was attributed through the inhibition of sLex 
biosynthesis134. Thus, the research was conducted on the CRC cell lines SW480 and 
SW620, originally lacking both Sda and sLex antigens, transfected with B4GALNT2 
or FUT6. This model allowed to analyze the effects on the CRC phenotype and 
transcriptome resulting from the de novo expression of the Sda or sLex antigens. The 
fact that the two cell lines were derived from the primary tumor (SW480) and a 
metastasis of the same patient (SW620), allowed to analyzed the effects of 
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glycosyltransferase expression on cells with a common genetic background but 
different malignancy.  
In SW620 cells, all the six properties associated with malignancy resulted down-
regulated by B4GALNT2 expression. On the contrary, in SW480 cells the 
proliferation rate and the wound healing capability were not affected. It appears that 
B4GALNT2 was able to inhibit specifically those properties, such as increased 
proliferation rate and ability to heal a wound, that were more pronounced in SW620 
due to their metastatic origin. It could be hypothesized that in SW620 cells 
proliferation is supplied by additional pathways, specifically inhibited by 
B4GALNT2.  FUT6 up-regulated the clonogenic ability in both SW480 and SW620, 
while the soft agar growth and the wound healing capability were up-regulated only 
in SW620. These data clearly show that the phenotypic changes induced by a 
glycosyltransferase are strongly dependent on the malignancy of the recipient cells. 
It could be hypothesized that this effect could be seen only if this ability is already 
present, as in SW620, but it could not be induced de novo if not present as in SW480 
cells. Apparently, the overexpression of FUT6, can exacerbate the phenotype only 
if the cell has previously reached a given “malignant threshold”.  The only features 
commonly inhibited by B4GALNT2 in all three cell lines were the ability to grow 
in poor adherence conditions and ALDH expression, all related with stemness. 
Importantly, these effects induced by B4GALNT2 were independent of sLex 
inhibition, as they were also found in cells lacking sLex antigen.  
 
Stemming from these results in vitro that highlight the strong impact of the 
B4GALNT2 expression on the phenotype of CRC cells, the project investigated also 
the effect of the glycosyltransferase expression on the transcriptome of transfected 
cell lines. The ability to modulate the transcriptome of cancer cells by a 
glycosyltransferase was previously reported. Nevertheless, the transcriptomic 
changes induced by B4GALNT2 in standard conditions of growth were surprisingly 
relevant.  
Among the most down-regulated genes in B4GALNT2-expressing clones with 
known functions in cancer there were nidogen-1 (NID1), galectin-2 (LGALS2), 
paternally expressed gene 10 (PEG10), retinoic acid induced 
(RAI14) and receptor-tyrosine-kinase-like orphan receptor 1 (ROR1); all of them are 
described in literature as cancer promoting genes. One of the most down-regulated 
genes in B4GALNT2-expressing clones was also the cancer stem cell related gene, 
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transcription factor SOX2, which belongs to the family of Sry related HMG Box 
proteins and is essential for the maintenance of self-renewal and pluripotency in 
embryonic stem cells as well as adult tissue progenitor cells135. SOX2 overexpression 
is correlated with tumorigenicity and CSC phenotype136. This gene is involved in 
pathways related with stemness, as displayed in GeneGO enrichment analysis. Its 
down-regulation may help to explain the reduced ability to grow in non-adherent 
conditions and the reduced number of stem cells observed in S2/S11 cells. On the 
other hand, another gene related with cancer stemness (CD200) was found to be the 
most up-regulated gene in B4GALNT2 transfectant clones. NGFRAP1 (nerve 
growth factor receptor-associated protein 1, also known as BEX3) which is involved 
in mitogenic signaling and apoptosis, was also up-regulated by B4GALNT2. 
The strong predominance of down-regulated genes over up-regulated genes in 
B4GALNT2-expressing cells may conceivably be related to a reduced ability to 
perform several cellular functions. The fact that the vast majority of these genes 
displayed cancer-promoting activity in different systems is consistent with an 
attenuation of the cancer phenotype in LS174T cells. Additionally, a causative role 
of B4GALNT2 in the control of these genes was enforced by the observation that in 
high and low B4GALNT2 expressers of the TCGA cohorts, the mean expression 
level of these genes, including SOX2, was in some cases significantly consistent with 
that observed in LS174T cells.  
 
Owing to the notably reduced ability to adapt to non-adherent growth displayed by 
B4GALNT2-expressing cells, the transcriptome of cells grown as spheroids in 3D 
conditions was also analyzed. The study focused on the genes modulated by 3D 
culture in LS174T cells as well as on those genes that displayed a differential 
response to 3D culture conditions in B4GALNT2-expressing cells S2/S11. The 
analysis showed that many genes were modulated by 3D culture conditions, 
regardless of B4GALNT2 expression. Among these, many genes were implicated in 
energy metabolism, including the glycolytic process, such as PFKFB4, PGM1, 
ALDOC, PGK1 and some were part of the hypoxia response (CA9, EGLN3, EGR1). 
Some of these genes were expressed at extremely high levels and were all up-
regulated including PGK1, LCN15, FABP1, ALDOC, PGM1, CA9.  This modulation 
could be explained by the notion that 3D cell models partially simulate the structure 
of the tumor microenvironment and cancer cells adapt their metabolism activating 
103 
 
the hypoxia response, resulting in increased glucose uptake and fermentation to 
foster proliferation, growth and survival137,138. 
The genes belonging to the transcriptional regulation group, such as those encoding 
the transcription factors FOS and FOSB and the transcriptional regulator EGR1, 
were highly expressed in  2D culture and dramatically down-regulated in 3D culture 
as alterations of transcriptional activity evolve during progression of 3D cultures 
similarly to in vivo microenvironment. On the other hand, among the genes involved 
in cell signaling, the gene KIT resulted up-regulated in 3D culture. This gene encodes 
a tyrosine-protein kinase acting as cell-surface receptor and playing an important 
role in the regulation of survival, proliferation and migration of cells. Genes involved 
in cytoskeleton organization displayed a general down-regulation as disorganization 
of cellular architecture is a common feature of tumors, while those involved in 
detoxification displayed up-regulation allowing cancer cells to grow in an otherwise 
toxic environment139. The genes PIGZ, involved in the biosynthesis of the 
glycosylphosphatidylinositol (GPI)-anchor, and NDRG1, involved in stress 
response, were found to be strongly upregulated.  
All the above-mentioned genes displayed 3D culture modulation regardless of 
B4GALNT2 expression. However, several genes displaying 3D culture modulation 
were identified only in S2/S11 cells; 13 genes were up-regulated while 18 were 
down-regulated. The most relevant change was the strong down-regulation of five 
genes regulating cytoskeletal organization in mitosis and motility including KIZ, 
CEP120, DNAH6, SGOL2, STARD13. This finding could explain the reduced ability 
to grow in non-adherent conditions observed in B4GALNT2-expressing cells. 
Among the genes controlling cell signaling, three genes encoding taste receptors 
(TAS2R45, TAS2R19, TAS2R30) appeared to be down-regulated. These genes are 
implicated in tasting bitterness but can also play a tumor-suppressive role. 3D culture 
augmented the propensity to apoptosis in B4GALNT2-expressing clones that can be 
explained through the modulation of at least three genes: TNFAIP8L2, MYOD1 and 
PPM1K. Among the genes involved in transcriptional regulation, PHF20L1 gene 
was remarkably downregulated, thus giving a contribution to explain the reduced 
stemness as it stabilizes the transcription factor SOX2 post-translationally. Three 
genes modulated by B4GALNT2 in 3D conditions were related to immunity and 
inflammation: CTLA4, a well-known inhibitory receptor of T lymphocytes; IL1A, an 
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inflammatory cytokine; TDO2, a gene involved in a pathway potentially suppressing 
anti-tumor immune responses. 
If it is assumed that 3D culture conditions in vitro are closer to those of in vivo 
growth, then it should be expected that high B4GALNT2-expressing tumors 
displayed modulation of the same genes we observed modulated by 3D only in 
B4GALNT2-expressing cells. This was true for all the genes falling in the groups 
“Cytoskeleton and mitosis” and “Transcription regulation”. Additionally, the gene 
TNFAIPL2, which promotes apoptosis, and the gene of the pro-inflammatory 
cytokine, IL1A, also were found to be consistently modulated in the TCGA cohort. 
Although IL1A plays different and even opposite roles in the tumor 
microenvironment, when it is expressed by CRC cells, it functions as an 
immunostimulatory molecule and enhances an anti-tumor immune response. 
Transcriptomic analysis of SW480 and SW620 cells expressing FUT6 or 
B4GALNT2 showed that FUT6 was able to modulate a higher number of genes than 
B4GALNT2 in both cell lines. Besides many genes regulated in parallel in the two 
cell lines, some were modulated only in one of the two and others were consistently 
modulated by either glycosyltransferase in the same cell line.  
Expression of FUT6 impacted on genes belonging to different functional classes in 
both cell lines: transcription, cell adhesion and cell signaling. However, this effect 
of FUT6 expression was cell-type specific. Indeed, in SW620 FUT6 expression 
heavily impacted on groups of genes which were poorly or unaffected in SW480, 
specifically genes directly involved in DNA duplication, such as the telomerase 
reverse transcriptase (TERT), the component of the DNA polymerase E-complex 
(POLE4), thymidylate synthase (TYMS), and the origin recognition complex 
member ORC6. Also genes related to cytoskeleton-cytokinesis, growth factor 
receptors, ion transport, cell signaling and transcription were more strongly affected 
by FUT6 in SW620 than in SW480. Unexpectedly, a few genes such as CYB5R2, 
DNAJC15, MVB12B and LIPC were subjected to opposite regulation by FUT6 in 
the two cell lines.  
Expression of B4GALNT2 strongly affected several functional classes in both cell 
lines including apoptosis, cytoskeleton and cytokinesis and transcription. However, 
even for B4GALNT2 the response was strongly cell line-specific. Indeed, a large 
group of genes involved in cytoskeleton organization and cytokinesis was modulated 
only in SW620, whereas a greater number of genes belonging to the transcription 
and growth factors classes were modulated by B4GALNT2 only in SW480 cells. To 
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be noted that a group of six SNAR [Small NF90 (ILF3) Associated RNAs], non-
protein coding RNAs with an unclear role in RNA function, were up-regulated only 
in SW480 cells.  
Amongst the genes more consistently down-regulated in both cell lines by 
B4GALNT2 is CD44. It has been documented that CD44 functions as a carrier of 
sLex100, and its fucosylated form allows CRC progression140. Thus, current data may 
contribute a new possible mechanism through which B4GALNT2 hinders cancer 
progression mediated by FUT6: besides the well reported competition for the 
carbohydrate substrate acceptor, through the down-regulation of one of the preferred 
sLex carriers. Down-regulation of CD44, considered a stemness marker92, is 
consistent with the reduced stemness induced by B4GALNT2 expression.  
Interestingly, a small number of genes were consistently modulated by either 
glycosyltransferase in the same cell line. To explain this unexpected observation it 
could be proposed that the presence of either the sLex or the Sda antigens on the same 
glycan receptor can, in some cases, produce a similar biological effect (for example 
the inhibition of the binding of a soluble factor). 
 
Owing to the marked cell specific effects on the transcriptome of glycosyltransferase 
overexpression observed in SW480 and SW620 cells,  the study intended to compare 
the effects of B4GALNT2 expression on the transcriptome of SW480 and SW620 
with those previously observed in B4GALNT2-transfected LS174T cells. Statistical 
analysis was thus performed in search of a “B4GALNT2 signature”, common to the 
three cell lines. Seven protein coding genes were identified: SPON2, PLL, 
FAM321A, MCOLN2, FILIP1L, COL20A1, BCL2L10. Among these genes, only 
MCOLN2 displayed up-regulation, while the remaining were down-regulated. 
Literature search reports a tumor promoting activity for MCOLN2, SPON2 and  
COL20A1 and a tumor restraining activity for FILIP1L and BCL2L10, while for 
PLLP and FAM231A no information were available.  Thus, changes of MCOLN2, 
FILIP1L and BCL2L10 would be tumor-promoting while changes of SPON2 and 
COL20A1 would be tumor-restraining. However, except for SPON2, which encodes 
an extracellular matrix protein promoting cell motility, growth and invasion of CRC, 
the level of expression of these genes was so low that they can hardly be responsible 





Overall, these data indicate that glycosyltransferases may induce a given phenotypic 
effect through the activation of multiple interconnected and converging pathways 
that are activated by different genes in a strongly cell-specific manner.  
In the clinic, the level of B4GALNT2 expressed by CRC tissues could be used to 
stratify patients according to their risk of progression. This aim is very important to 
avoid invasive and expensive therapies to low risk patients. In this light, it is crucial 
to understand the ways through which B4GALNT2 and its associated Sda antigen 
have a tumor restraining effect in CRC. This study provides evidence that the tumor 
restraining activity was not exerted only through sLex inhibition, otherwise it was 
not working in sLex-negative cases. On the contrary, it is largely independent of sLex 



























TAKE HOME MESSAGES 
 
 
 B4GALNT2 glycosyltransferases attenuates malignancy of CRC by reducing 
stemness of CRC cells. 
 This effect is independent on sLex inhibition. 
 Both FUT6 and B4GALNT2 are able to modulate the CRC transcriptome. 
 The impact of glycosyltransferase overexpression is strongly cell-type specific. 
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